Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology/Oncology, Medicine, Duke University 1994 - 1997
  • Medical Resident, Medicine, Duke University 1991 - 1994
  • M.D., University of Rochester 1991
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2007 - 2013
  • Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2003 - 2007
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1998 - 2003
  • Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1997 - 1998
• Research
• 

  Selected Grants

  • SGI 110 12 2018 - 2023
  • Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia 2018 - 2023
  • PF-04449913 (Glasdegib) in Combination with Azacitidine 2018 - 2023
  • Protocol 2215-CL-9100 2018 - 2023
  • Protocol Number NLA-0101-CIN-01 2018 - 2023
  • 2102 HEM 101 2018 - 2023
  • MEI-011 2017 - 2022
  • AG-120 2017 - 2022
  • Venetoclax (ABT-199/GDC-0199) in combination with Azacitidine 2017 - 2022
  • Phase I/II Study of Lintuzumab-Ac225 AML 2017 - 2022
  • A Phase 3 Multicenter, Randomized, Open Label study of Guadecitabine 2017 - 2022
  • Postdoctoral Training in Genomic Medicine Research awarded by National Institutes of Health 2017 - 2022
  • Phase 1 Study of ABBV-075 2017 - 2022
  • Efficacy study of Inecalitol in combination with Decitabine in Acute Myeloid Patients unfit for standard chemotherapy 2016 - 2021
  • MEDI D4190C00023 2016 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • Phase III study of ASP2215 vs Salvage Chemo in pts with R/R AML with FLT3 mutation 2016 - 2020
  • Breaking B-Cell Tolerance to Produce Antibodies that Eradicate Leukemias and Lymphomas awarded by Department of Defense 2018 - 2020
  • Quizartinib AC220-007 2015 - 2020
  • Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD awarded by National Institutes of Health 2015 - 2020
  • Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD awarded by National Institutes of Health 2015 - 2020
  • SL-401 with AML patients 2014 - 2020
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2020
  • A Phase 1 Dose Escalation Study of MDG006 in Patients with Relapsed or Refractory AML 2015 - 2020
  • Phase I Study of ABT-199 in comb w/ Aza or Dec with AML patients ho are > 65 y/o 2014 - 2019
  • PRAN-16-52 2018 - 2019
  • Phase 1 study of ER190LI - ARTEMIS T Cells in Relapsed and Refractory CD19 + Non-Hodgkin's Lymphoma 2018 - 2019
  • TPI-ALV-201 2017 - 2019
  • Phase I study of ADCT-301 in CD25+ AML 2016 - 2019
  • Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes awarded by Memorial Sloan Kettering Cancer Center 2017 - 2019
  • A phase 3 study of SGI-110 vs Treatment Choice for AML patients not candidates for chemotherapy 2016 - 2019
  • CA212016 BMS 2018 - 2019
  • Phase I study of L-asparaginase encapsulated in red blood cells (ERYASP) 2014 - 2018
  • Phase 2 of SY-1425 2016 - 2018
  • Phase II study of SINE (KPT-330) vs SOC in patients with R/R AML 2015 - 2018
  • Development of the Phase I study involving ET190L1-Artemis in CD19 positive blood malignancies 2016 - 2018
  • Phase 3 Guadecitabine (SGI-110-07) 2017 - 2018
  • Stemline Phase II 2015 - 2018
  • Improving Outcomes of Older and Medically Infirm Patients with AML 2015 - 2018
  • Phase I/II Pri-724 for Advanced Myeloid Malignancies 2014 - 2018
  • Phase 1/1b, First-in-Human FLX925 for R/R AML 2015 - 2018
  • Randomized Phase II study of CX-01 combined with standard induction therapy for newly diagnosed AML 2016 - 2017
  • Phase 2, Randomized, Double-Blind, Placebo-Controlled study of Azacitidine with or without Birinapant 2014 - 2017
  • A Multicenter Phase III Rand, open-Label, study of Bosutinib vs Imatinib in adults with newly diagnosed CPCML 2014 - 2017
  • Kalobios Ph1/2 KB004 for EphA3-Expressing Hematologic Malignancies (KB004-01) 2015 - 2016
  • Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
  • Mechanisms of lung injury following autologous BMT awarded by National Institutes of Health 2003 - 2007
  • Mentored Patient-Oriented Research Career Dev Award awarded by National Institutes of Health 2000 - 2005
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Kam, Angel Y. F., Sadhna O. Piryani, Chad M. McCall, Hee Su Park, David A. Rizzieri, and Phuong L. Doan. “Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome..” Clin Cancer Res 25, no. 13 (July 1, 2019): 4155–67. https://doi.org/10.1158/1078-0432.CCR-18-3517.
       Full Text  Link to Item
    • Lin, Kevin H., Abigail Xie, Justine C. Rutter, Yeong-Ran Ahn, Julia M. Lloyd-Cowden, Amanda G. Nichols, Ryan S. Soderquist, et al. “Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity..” Cell Metab 29, no. 5 (May 7, 2019): 1217-1231.e7. https://doi.org/10.1016/j.cmet.2019.01.011.
       Full Text  Link to Item
    • Pemmaraju, Naveen, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm..” N Engl J Med 380, no. 17 (April 25, 2019): 1628–37. https://doi.org/10.1056/NEJMoa1815105.
       Full Text  Link to Item
    • Hudson, Kathryn E., David Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis Diehl, Joseph O. Moore, Carlos DeCastro, and Anne W. Beaven. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study..” Br J Haematol 184, no. 4 (February 2019): 647–50. https://doi.org/10.1111/bjh.15138.
       Full Text  Link to Item
    • Berdeja, J. G., M. C. Heinrich, S. R. Dakhil, S. L. Goldberg, M. Wadleigh, P. Kuriakose, J. Cortes, et al. “Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.” Leukemia and Lymphoma, January 1, 2019. https://doi.org/10.1080/10428194.2019.1590569.
       Full Text
    • Heyman, Benjamin, David Rizzieri, David J. Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore, and Anne Beaven. “Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma..” Clin Lymphoma Myeloma Leuk 18, no. 10 (October 2018): 679–86. https://doi.org/10.1016/j.clml.2018.07.285.
       Full Text  Link to Item
    • Zeidan, Amer M., Hanna A. Knaus, Tara M. Robinson, Andrea M. H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, et al. “A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure..” Clin Cancer Res 24, no. 15 (August 1, 2018): 3519–27. https://doi.org/10.1158/1078-0432.CCR-17-3763.
       Full Text  Link to Item
    • Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma..” Blood Cancer J 8, no. 8 (July 31, 2018). https://doi.org/10.1038/s41408-018-0104-5.
       Full Text  Link to Item
    • Stein, Eytan M., Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Michael R. Savona, Mojca Jongen-Lavrenic, et al. “The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia..” Blood 131, no. 24 (June 14, 2018): 2661–69. https://doi.org/10.1182/blood-2017-12-818948.
       Full Text  Link to Item
    • Casulo, Carla, Jonathan W. Friedberg, Kwang W. Ahn, Christopher Flowers, Alyssa DiGilio, Sonali M. Smith, Sairah Ahmed, et al. “Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis..” Biol Blood Marrow Transplant 24, no. 6 (June 2018): 1163–71. https://doi.org/10.1016/j.bbmt.2017.12.771.
       Full Text  Link to Item
    • Kebriaei, Partow, Claudio Anasetti, Mei-Jie Zhang, Hai-Lin Wang, Ibrahim Aldoss, Marcos de Lima, H Jean Khoury, et al. “Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia..” Biol Blood Marrow Transplant 24, no. 4 (April 2018): 726–33. https://doi.org/10.1016/j.bbmt.2017.11.025.
       Full Text  Link to Item
    • Roboz, Gail J., Hagop M. Kantarjian, Karen W. L. Yee, Patricia L. Kropf, Casey L. O’Connell, Elizabeth A. Griffiths, Wendy Stock, et al. “Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia..” Cancer 124, no. 2 (January 15, 2018): 325–34. https://doi.org/10.1002/cncr.31138.
       Full Text  Link to Item
    • Guo, Mei, Nelson J. Chao, Jian-Yong Li, David A. Rizzieri, Qi-Yun Sun, Ann Mohrbacher, Elizabeth F. Krakow, et al. “HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group..” Jama Oncol 4, no. 1 (January 1, 2018): 54–62. https://doi.org/10.1001/jamaoncol.2017.2656.
       Full Text  Link to Item
    • O’Brien, J., T. Rizzieri, and D. Rizzieri. “Recombinant human fusion protein of diphtheria toxin and IL-3 treatment of blastic plasmacytoid dendritic cell neoplasm.” Drugs of the Future 43, no. 12 (January 1, 2018): 873–80. https://doi.org/10.1358/dof.2018.043.12.2898664.
       Full Text
    • Sivaraj, D., W. Bacon, G. D. Long, D. A. Rizzieri, M. E. Horwitz, K. M. Sullivan, Y. Kang, Z. Li, N. J. Chao, and C. Gasparetto. “High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma..” Bone Marrow Transplant 53, no. 1 (January 2018): 34–38. https://doi.org/10.1038/bmt.2017.208.
       Full Text  Link to Item
    • Wong, Hong Yuen, Anthony D. Sung, Katherine E. Lindblad, Sheenu Sheela, Gregory W. Roloff, David Rizzieri, Meghali Goswami, et al. “Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response..” Front Oncol 8 (2018). https://doi.org/10.3389/fonc.2018.00669.
       Full Text  Link to Item
    • Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M. Sullivan, et al. “Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma..” Hematol Oncol 35, no. 4 (December 2017): 752–59. https://doi.org/10.1002/hon.2379.
       Full Text  Link to Item
    • Kantarjian, Hagop M., Gail J. Roboz, Patricia L. Kropf, Karen W. L. Yee, Casey L. O’Connell, Raoul Tibes, Katherine J. Walsh, et al. “Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial..” Lancet Oncol 18, no. 10 (October 2017): 1317–26. https://doi.org/10.1016/S1470-2045(17)30576-4.
       Full Text  Link to Item
    • Muffly, Lori, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, et al. “Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States..” Blood 130, no. 9 (August 31, 2017): 1156–64. https://doi.org/10.1182/blood-2017-03-772368.
       Full Text  Link to Item
    • Batlevi, Connie L., Michael Crump, Charalambos Andreadis, David Rizzieri, Sarit E. Assouline, Susan Fox, Richard H. C. van der Jagt, et al. “A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma..” Br J Haematol 178, no. 3 (August 2017): 434–41. https://doi.org/10.1111/bjh.14698.
       Full Text  Link to Item
    • Boss, M. K., M. W. Dewhirst, R. S. Sampaio, A. Bennett, A. Tovmasyan, K. G. Berman, A. W. Beaven, et al. “Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy..” Cancer Chemother Pharmacol 80, no. 2 (August 2017): 421–31. https://doi.org/10.1007/s00280-017-3372-z.
       Full Text  Link to Item
    • Anand, Sarah, Samantha Thomas, Terry Hyslop, Janet Adcock, Kelly Corbet, Cristina Gasparetto, Richard Lopez, et al. “Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization..” Biol Blood Marrow Transplant 23, no. 7 (July 2017): 1151–57. https://doi.org/10.1016/j.bbmt.2017.04.001.
       Full Text  Link to Item
    • Michelis, Fotios V., Vikas Gupta, Mei-Jie Zhang, Hai-Lin Wang, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjaneh, et al. “Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis..” Cancer 123, no. 11 (June 1, 2017): 2035–42. https://doi.org/10.1002/cncr.30567.
       Full Text  Link to Item
    • El-Jawahri, Areej, Yi-Bin Chen, Ruta Brazauskas, Naya He, Stephanie J. Lee, Jennifer M. Knight, Navneet Majhail, et al. “Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation..” Cancer 123, no. 10 (May 15, 2017): 1828–38. https://doi.org/10.1002/cncr.30546.
       Full Text  Link to Item
    • Liu, Hien Duong, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, et al. “Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia..” Biol Blood Marrow Transplant 23, no. 5 (May 2017): 767–75. https://doi.org/10.1016/j.bbmt.2017.01.078.
       Full Text  Link to Item
    • Sivaraj, Dharshan, Michael M. Green, Zhiguo Li, Anthony D. Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn D. Long, et al. “Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma..” Biol Blood Marrow Transplant 23, no. 2 (February 2017): 262–68. https://doi.org/10.1016/j.bbmt.2016.11.010.
       Full Text  Link to Item
    • Sullivan, Jill M., and David A. Rizzieri. “Treatment of blastic plasmacytoid dendritic cell neoplasm..” Hematology Am Soc Hematol Educ Program 2016, no. 1 (December 2, 2016): 16–23. https://doi.org/10.1182/asheducation-2016.1.16.
       Full Text  Link to Item
    • Bajaj, Jeevisha, Takaaki Konuma, Nikki K. Lytle, Hyog Young Kwon, Jailal N. Ablack, Joseph M. Cantor, David Rizzieri, et al. “CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia..” Cancer Cell 30, no. 5 (November 14, 2016): 792–805. https://doi.org/10.1016/j.ccell.2016.10.003.
       Full Text  Link to Item
    • Sung, Anthony D., Julia A. M. Sung, Samantha Thomas, Terry Hyslop, Cristina Gasparetto, Gwynn Long, David Rizzieri, et al. “Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial..” Clin Infect Dis 63, no. 8 (October 15, 2016): 999–1006. https://doi.org/10.1093/cid/ciw451.
       Full Text  Link to Item
    • Zahid, Mohammad Faizan, Mrinal M. Patnaik, Naseema Gangat, Shahrukh K. Hashmi, and David A. Rizzieri. “Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy..” Eur J Haematol 97, no. 4 (October 2016): 313–20. https://doi.org/10.1111/ejh.12771.
       Full Text  Link to Item
    • Rizzieri, David. “Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?.” Crit Rev Oncol Hematol 105 (September 2016): 5–17. https://doi.org/10.1016/j.critrevonc.2016.07.008.
       Full Text  Link to Item
    • Green, Michael M. B., Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, et al. “Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery..” J Hematol Oncol 9, no. 1 (August 17, 2016). https://doi.org/10.1186/s13045-016-0301-2.
       Full Text  Open Access Copy  Link to Item
    • Rizzieri, David A., Sarah Cooley, Olatoyosi Odenike, Lisette Moonan, Kay Hoong Chow, Kimberley Jackson, Xuejing Wang, Leslie Brail, and Gautam Borthakur. “An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia..” Leuk Lymphoma 57, no. 8 (August 2016): 1800–1806. https://doi.org/10.3109/10428194.2015.1122781.
       Full Text  Link to Item
    • Shaffer, Brian C., Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, et al. “Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome..” J Clin Oncol 34, no. 16 (June 1, 2016): 1864–71. https://doi.org/10.1200/JCO.2015.65.0515.
       Full Text  Link to Item
    • Zahid, Mohammad Faizan, and David Alan Rizzieri. “Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders..” Adv Hematol 2016 (2016). https://doi.org/10.1155/2016/1423493.
       Full Text  Link to Item
    • Urbano-Ispizua, Alvaro, Steven Z. Pavletic, Mary E. Flowers, John P. Klein, Mei-Jie Zhang, Jeanette Carreras, Silvia Montoto, et al. “The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen..” Biol Blood Marrow Transplant 21, no. 10 (October 2015): 1746–53. https://doi.org/10.1016/j.bbmt.2015.05.010.
       Full Text  Link to Item
    • Griffin, Patrick T., Rami S. Komrokji, Carlos M. De Castro, David A. Rizzieri, Magda Melchert, Alan F. List, and Jeffrey E. Lancet. “A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy..” Am J Hematol 90, no. 9 (September 2015): 796–99. https://doi.org/10.1002/ajh.24087.
       Full Text  Link to Item
    • Issa, Jean-Pierre J., Gail Roboz, David Rizzieri, Elias Jabbour, Wendy Stock, Casey O’Connell, Karen Yee, et al. “Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study..” Lancet Oncol 16, no. 9 (September 2015): 1099–1110. https://doi.org/10.1016/S1470-2045(15)00038-8.
       Full Text  Link to Item
    • Kwon, Hyog Young, Jeevisha Bajaj, Takahiro Ito, Allen Blevins, Takaaki Konuma, Joi Weeks, Nikki K. Lytle, et al. “Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia..” Cell Stem Cell 17, no. 2 (August 6, 2015): 152–64. https://doi.org/10.1016/j.stem.2015.06.006.
       Full Text  Link to Item
    • Tuchman, Sascha A., Wendi A. Bacon, Li-Wen Huang, Gwynn Long, David Rizzieri, Mitchell Horwitz, John P. Chute, et al. “Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma..” J Clin Apher 30, no. 3 (June 2015): 176–82. https://doi.org/10.1002/jca.21360.
       Full Text  Link to Item
    • Davis, C. T., and D. Rizzieri. “Immunotherapeutic applications of NK cells.” Pharmaceuticals 8, no. 2 (May 8, 2015): 250–56. https://doi.org/10.3390/ph8020250.
       Full Text
    • Stone, Richard M., Emanuele Mazzola, Donna Neuberg, Steven L. Allen, Arnaud Pigneux, Robert K. Stuart, Meir Wetzler, et al. “Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia..” J Clin Oncol 33, no. 11 (April 10, 2015): 1252–57. https://doi.org/10.1200/JCO.2014.57.0952.
       Full Text  Link to Item
    • Bachanova, V., L. J. Burns, T. Wang, J. Carreras, R. P. Gale, P. H. Wiernik, K. K. Ballen, et al. “Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.” Bone Marrow Transplantation 50, no. 2 (February 7, 2015): 197–203. https://doi.org/10.1038/bmt.2014.259.
       Full Text
    • Bachanova, V., L. J. Burns, T. Wang, J. Carreras, R. P. Gale, P. H. Wiernik, K. K. Ballen, et al. “Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor..” Bone Marrow Transplant 50, no. 2 (February 2015): 197–203. https://doi.org/10.1038/bmt.2014.259.
       Full Text  Link to Item
    • Chen, Weihong, David Rizzieri, and Susan Drago. “Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000/µl..” J Clin Apher 30, no. 1 (February 2015): 28–31. https://doi.org/10.1002/jca.21343.
       Full Text  Link to Item
    • Tuchman, S. A., W. A. Bacon, L. W. Huang, G. Long, D. Rizzieri, M. Horwitz, J. P. Chute, et al. “Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.” Journal of Clinical Apheresis 30, no. 3 (January 1, 2015): 176–82. https://doi.org/10.1002/jca.21360.
       Full Text
    • Stein, Eytan M., Guillermo Garcia-Manero, David A. Rizzieri, Michael Savona, Raoul Tibes, Jessica K. Altman, Mojca Jongen-Lavrencic, et al. “The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia.” Blood 124, no. 21 (December 6, 2014).
       Link to Item
    • Rein, Lindsay A. M., and David A. Rizzieri. “Clinical potential of elacytarabine in patients with acute myeloid leukemia..” Ther Adv Hematol 5, no. 6 (December 2014): 211–20. https://doi.org/10.1177/2040620714552615.
       Full Text  Link to Item
    • Hamadani, M., P. N. Hari, Y. Zhang, J. Carreras, G. Akpek, M. D. Aljurf, E. Ayala, et al. “Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation 20, no. 11 (November 1, 2014): 1729–36. https://doi.org/10.1016/j.bbmt.2014.06.036.
       Full Text
    • Hamadani, Mehdi, Parameswaran N. Hari, Ying Zhang, Jeanette Carreras, Görgün Akpek, Mahmoud D. Aljurf, Ernesto Ayala, et al. “Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation..” Biol Blood Marrow Transplant 20, no. 11 (November 2014): 1729–36. https://doi.org/10.1016/j.bbmt.2014.06.036.
       Full Text  Link to Item
    • Liu, T., R. J. Kishton, A. N. Macintyre, V. A. Gerriets, H. Xiang, X. Liu, E. D. Abel, D. Rizzieri, J. W. Locasale, and J. C. Rathmell. “Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis..” Cell Death Dis 5 (October 16, 2014). https://doi.org/10.1038/cddis.2014.431.
       Full Text  Link to Item
    • Rizzieri, David, Norbert Vey, Xavier Thomas, Françoise Huguet-Rigal, Richard F. Schlenk, Jürgen Krauter, Thomas Kindler, et al. “A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course..” Leuk Lymphoma 55, no. 9 (September 2014): 2114–19. https://doi.org/10.3109/10428194.2013.867489.
       Full Text  Link to Item
    • Horwitz, Mitchell E., Nelson J. Chao, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, Cristina Gasparetto, John P. Chute, et al. “Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment..” J Clin Invest 124, no. 7 (July 2014): 3121–28. https://doi.org/10.1172/JCI74556.
       Full Text  Link to Item
    • Wirk, Baldeep, Timothy S. Fenske, Mehdi Hamadani, Mei-Jie Zhang, Zhen-Huan Hu, Görgün Akpek, Mahmoud D. Aljurf, et al. “Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma..” Biol Blood Marrow Transplant 20, no. 7 (July 2014): 951–59. https://doi.org/10.1016/j.bbmt.2014.03.014.
       Full Text  Link to Item
    • Rizzieri, David A., Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, et al. “Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002..” Br J Haematol 165, no. 1 (April 2014): 102–11. https://doi.org/10.1111/bjh.12736.
       Full Text  Link to Item
    • Allen, Jessica L., Prasanthi V. Tata, Matthew S. Fore, Jenna Wooten, Sharmistha Rudra, Allison M. Deal, Andrew Sharf, et al. “Increased BCR responsiveness in B cells from patients with chronic GVHD..” Blood 123, no. 13 (March 27, 2014): 2108–15. https://doi.org/10.1182/blood-2013-10-533562.
       Full Text  Link to Item
    • Fenske, Timothy S., Mei-Jie Zhang, Jeanette Carreras, Ernesto Ayala, Linda J. Burns, Amanda Cashen, Luciano J. Costa, et al. “Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality..” J Clin Oncol 32, no. 4 (February 1, 2014): 273–81. https://doi.org/10.1200/JCO.2013.49.2454.
       Full Text  Link to Item
    • Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, et al. “Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies..” Biol Blood Marrow Transplant 20, no. 2 (February 2014): 257–63. https://doi.org/10.1016/j.bbmt.2013.11.010.
       Full Text  Link to Item
    • Rizzieri, David. “Is timing everything?.” Biol Blood Marrow Transplant 20, no. 2 (February 2014): 145–46. https://doi.org/10.1016/j.bbmt.2013.12.556.
       Full Text  Link to Item
    • Chen, W., D. Rizzieri, and S. Drago. “Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000/μl.” Journal of Clinical Apheresis, 2014. https://doi.org/10.1002/jca.21343.
       Full Text
    • Liu, T., R. J. Kishton, A. N. Macintyre, V. A. Gerriets, H. Xiang, X. Liu, E. D. Abel, D. Rizzieri, J. W. Locasale, and J. C. Rathmell. “Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis..” Cell Death Dis 5 (2014). https://doi.org/10.1038/cddis.2014.493.
       Full Text  Link to Item
    • Rizzieri, D. A., J. L. Johnson, J. C. Byrd, G. Lozanski, K. A. Blum, B. L. Powell, T. C. Shea, et al. “Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002.” British Journal of Haematology 165, no. 1 (January 1, 2014): 102–11. https://doi.org/10.1111/bjh.12736.
       Full Text
    • Wirk, B., T. S. Fenske, M. Hamadani, M. J. Zhang, Z. H. Hu, G. Akpek, M. D. Aljurf, et al. “Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma.” Biology of Blood and Marrow Transplantation 20, no. 7 (January 1, 2014): 951–59. https://doi.org/10.1016/j.bbmt.2014.03.014.
       Full Text
    • Zimdahl, B., T. Ito, A. Blevins, J. Bajaj, T. Konuma, J. Weeks, C. S. Koechlein, et al. “Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.” Nature Genetics 46, no. 3 (January 1, 2014): 245–52. https://doi.org/10.1038/ng.2889.
       Full Text
    • Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma..” Leuk Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.
       Full Text  Link to Item
    • Armand, Philippe, Arnon Nagler, Edie A. Weller, Steven M. Devine, David E. Avigan, Yi-Bin Chen, Mark S. Kaminski, et al. “Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial..” J Clin Oncol 31, no. 33 (November 20, 2013): 4199–4206. https://doi.org/10.1200/JCO.2012.48.3685.
       Full Text  Link to Item
    • Lee, Stephanie J., Barry Storer, Hailin Wang, Hillard M. Lazarus, Edmund K. Waller, Luis M. Isola, Thomas R. Klumpp, et al. “Providing personalized prognostic information for adult leukemia survivors..” Biol Blood Marrow Transplant 19, no. 11 (November 2013): 1600–1607. https://doi.org/10.1016/j.bbmt.2013.08.013.
       Full Text  Link to Item
    • Maziarz, Richard T., Zhiwei Wang, Mei-Jie Zhang, Brian J. Bolwell, Andy I. Chen, Timothy S. Fenske, Cesar O. Freytes, et al. “Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement..” Br J Haematol 162, no. 5 (September 2013): 648–56. https://doi.org/10.1111/bjh.12451.
       Full Text  Link to Item
    • Kanda, J., L. Kaynar, Y. Kanda, V. K. Prasad, S. H. Parikh, L. Lan, T. Shen, et al. “Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment..” Bone Marrow Transplant 48, no. 7 (July 2013): 926–31. https://doi.org/10.1038/bmt.2012.279.
       Full Text  Link to Item
    • Lim, Sharon, Tzuen Yih Saw, Min Zhang, Matthew R. Janes, Kassoum Nacro, Jeffrey Hill, An Qi Lim, et al. “Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function..” Proceedings of the National Academy of Sciences of the United States of America 110, no. 25 (June 4, 2013): E2298–2307. https://doi.org/10.1073/pnas.1301838110.
       Full Text
    • Hamadani, Mehdi, Wael Saber, Kwang Woo Ahn, Jeanette Carreras, Mitchell S. Cairo, Timothy S. Fenske, Robert Peter Gale, et al. “Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma..” Biol Blood Marrow Transplant 19, no. 5 (May 2013): 746–53. https://doi.org/10.1016/j.bbmt.2013.01.024.
       Full Text  Link to Item
    • O’Brien, J. A., and D. A. Rizzieri. “Leukemic stem cells: a review..” Cancer Invest 31, no. 4 (May 2013): 215–20. https://doi.org/10.3109/07357907.2012.700986.
       Full Text  Link to Item
    • Cortes, Jorge, Eric Feldman, Karen Yee, David Rizzieri, Anjali S. Advani, Anthony Charman, Richard Spruyt, Martin Toal, and Hagop Kantarjian. “Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study..” Lancet Oncol 14, no. 4 (April 2013): 354–62. https://doi.org/10.1016/S1470-2045(13)70037-8.
       Full Text  Link to Item
    • Hamadani, Mehdi, Wael Saber, Kwang Woo Ahn, Jeanette Carreras, Mitchell S. Cairo, Timothy S. Fenske, Robert Peter Gale, et al. “Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research..” Biol Blood Marrow Transplant 19, no. 4 (April 2013): 625–31. https://doi.org/10.1016/j.bbmt.2013.01.009.
       Full Text  Link to Item
    • Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.
       Full Text  Link to Item
    • Kurokawa, Manabu, Takahiro Ito, Chih-Sheng Yang, Chen Zhao, Andrew N. Macintyre, David A. Rizzieri, Jeffrey C. Rathmell, Michael W. Deininger, Tannishtha Reya, and Sally Kornbluth. “Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells..” Proc Natl Acad Sci U S A 110, no. 6 (February 5, 2013): 2300–2305. https://doi.org/10.1073/pnas.1206551110.
       Full Text  Open Access Copy  Link to Item
    • Maramattom, Leena V., Parameswaran N. Hari, Linda J. Burns, Jeanette Carreras, William Arcese, Mitchell S. Cairo, Luciano J. Costa, et al. “Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research..” Biol Blood Marrow Transplant 19, no. 2 (February 2013): 173–79. https://doi.org/10.1016/j.bbmt.2012.11.016.
       Full Text  Link to Item
    • Rein, Lindsay Am, Anthony D. Sung, and David A. Rizzieri. “New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation..” Int J Hematol Oncol 2, no. 1 (February 2013). https://doi.org/10.2217/ijh.13.4.
       Full Text  Link to Item
    • Zhang, Jenny, Vladimir Grubor, Cassandra L. Love, Anjishnu Banerjee, Kristy L. Richards, Piotr A. Mieczkowski, Cherie Dunphy, et al. “Genetic heterogeneity of diffuse large B-cell lymphoma..” Proc Natl Acad Sci U S A 110, no. 4 (January 22, 2013): 1398–1403. https://doi.org/10.1073/pnas.1205299110.
       Full Text  Link to Item
    • Cortes, J., E. Feldman, K. Yee, D. Rizzieri, A. S. Advani, A. Charman, R. Spruyt, M. Toal, and H. Kantarjian. “Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): A randomised open-label phase 2 study.” The Lancet Oncology 14, no. 4 (2013): 354–62. https://doi.org/10.1016/S1470-2045(13)70037-8.
       Full Text
    • Giles, F. J., R. T. Swords, A. Nagler, A. Hochhaus, O. G. Ottmann, D. A. Rizzieri, M. Talpaz, et al. “MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia..” Leukemia 27, no. 1 (January 2013): 113–17. https://doi.org/10.1038/leu.2012.186.
       Full Text  Link to Item
    • Giles, F. J., R. T. Swords, A. Nagler, A. Hochhaus, O. G. Ottmann, D. A. Rizzieri, M. Talpaz, et al. “MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.” Leukemia 27, no. 1 (2013): 113–17. https://doi.org/10.1038/leu.2012.186.
       Full Text
    • Kanda, J., L. Kaynar, Y. Kanda, V. K. Prasad, S. H. Parikh, L. Lan, T. Shen, et al. “Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: Risk factors and response to treatment.” Bone Marrow Transplantation 48, no. 7 (2013): 926–31. https://doi.org/10.1038/bmt.2012.279.
       Full Text
    • Klepin, Heidi D., David Rizzieri, Antonio Palumbo, Valeria Magarotto, and Barbara Eichhorst. “Individualizing treatment decisions for older adults with hematologic malignancies..” Am Soc Clin Oncol Educ Book, 2013, 208–19. https://doi.org/10.1200/EdBook_AM.2013.33.208.
       Full Text  Link to Item
    • Maziarz, R. T., Z. Wang, M. J. Zhang, B. J. Bolwell, A. I. Chen, T. S. Fenske, C. O. Freytes, et al. “Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.” British Journal of Haematology 162, no. 5 (2013): 648–56. https://doi.org/10.1111/bjh.12451.
       Full Text
    • Morris, Tod A., Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Zhiguo Li, Joseph O. Moore, David A. Rizzieri, and Arati V. Rao. “Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia..” Leuk Res 37, no. 1 (January 2013): 28–31. https://doi.org/10.1016/j.leukres.2012.09.016.
       Full Text  Link to Item
    • Rizzieri, David A. “MDS: unraveling the mystery..” Blood 120, no. 25 (December 13, 2012): 4906–8. https://doi.org/10.1182/blood-2012-09-452755.
       Full Text  Link to Item
    • Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney Miles, Kristy L. Richards, et al. “The genetic landscape of mutations in Burkitt lymphoma..” Nat Genet 44, no. 12 (December 2012): 1321–25. https://doi.org/10.1038/ng.2468.
       Full Text  Link to Item
    • Kanda, Junya, Lun-Wei Chiou, Paul Szabolcs, Gregory D. Sempowski, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, et al. “Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation..” Biol Blood Marrow Transplant 18, no. 11 (November 2012): 1664-1676.e1. https://doi.org/10.1016/j.bbmt.2012.06.005.
       Full Text  Link to Item
    • Spasojevic, Ivan, Ligia R. S. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry..” Cancer Invest 30, no. 9 (November 2012): 679–82. https://doi.org/10.3109/07357907.2012.726386.
       Full Text  Link to Item
    • Rizzieri, D, and Moore, JO. "Implementation of management guidelines for chronic myeloidl leukemia perspectives in the United States." P and T 37, no. 11 (November 1, 2012): 640-648.
    • O’Brien, Susan, David A. Rizzieri, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, Mike Dennis, et al. “Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia..” Br J Haematol 158, no. 5 (September 2012): 581–88. https://doi.org/10.1111/j.1365-2141.2012.09186.x.
       Full Text  Link to Item
    • Horwitz, M. E., J. P. Chute, C. Gasparetto, G. D. Long, C. McDonald, A. Morris, D. A. Rizzieri, K. M. Sullivan, and N. J. Chao. “Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration..” Bone Marrow Transplant 47, no. 8 (August 2012): 1051–55. https://doi.org/10.1038/bmt.2011.217.
       Full Text  Link to Item
    • Faderl, Stefan, Meir Wetzler, David Rizzieri, Gary Schiller, Madan Jagasia, Robert Stuart, Siddhartha Ganguly, et al. “Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial..” J Clin Oncol 30, no. 20 (July 10, 2012): 2492–99. https://doi.org/10.1200/JCO.2011.37.9743.
       Full Text  Link to Item
    • Giles, F. J., N. Vey, D. Rizzieri, F. Ravandi, T. Prebet, G. Borthakur, T. F. Jacobsen, S. Hagen, B. Nilsson, and S. O’Brien. “Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies..” Leukemia 26, no. 7 (July 2012): 1686–89. https://doi.org/10.1038/leu.2012.1.
       Full Text  Link to Item
    • Hale, Gregory A., Smriti Shrestha, Jennifer Le-Rademacher, Linda J. Burns, John Gibson, David J. Inwards, Cesar O. Freytes, et al. “Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR..” Biol Blood Marrow Transplant 18, no. 7 (July 2012): 1036-1043.e1. https://doi.org/10.1016/j.bbmt.2011.11.026.
       Full Text  Link to Item
    • Pettengell, Ruth, Bertrand Coiffier, Geetha Narayanan, Fernando Hurtado de Mendoza, Raghunadharao Digumarti, Henry Gomez, Pier Luigi Zinzani, et al. “Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial..” Lancet Oncol 13, no. 7 (July 2012): 696–706. https://doi.org/10.1016/S1470-2045(12)70212-7.
       Full Text  Link to Item
    • Rao, A. V., D. A. Rizzieri, C. M. DeCastro, L. F. Diehl, A. S. Lagoo, J. O. Moore, and J. P. Gockerman. “Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML.” Journal of Geriatric Oncology 3, no. 3 (July 1, 2012): 220–27. https://doi.org/10.1016/j.jgo.2012.02.002.
       Full Text
    • Chen, D. -. F., V. K. Prasad, G. Broadwater, N. L. Reinsmoen, A. DeOliveira, A. Clark, K. M. Sullivan, et al. “Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors..” Bone Marrow Transplant 47, no. 6 (June 2012): 817–23. https://doi.org/10.1038/bmt.2011.181.
       Full Text  Link to Item
    • Khoury, H. J., M. Kukreja, J. M. Goldman, T. Wang, J. Halter, M. Arora, V. Gupta, et al. “Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis..” Bone Marrow Transplant 47, no. 6 (June 2012): 810–16. https://doi.org/10.1038/bmt.2011.194.
       Full Text  Link to Item
    • Kanda, J., M. E. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. P. Chute, A. Morris, et al. “Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation..” Bone Marrow Transplant 47, no. 5 (May 2012): 700–705. https://doi.org/10.1038/bmt.2011.158.
       Full Text  Link to Item
    • Giles, Francis, David Rizzieri, Farhad Ravandi, Ronan Swords, Tove Flem Jacobsen, and Susan O’Brien. “Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia..” Leuk Res 36, no. 4 (April 2012): e71–73. https://doi.org/10.1016/j.leukres.2011.12.010.
       Full Text  Link to Item
    • Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia..” Leuk Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.
       Full Text  Link to Item
    • Rizzieri, David A., and Katherine Walsh. “Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria..” Clin Adv Hematol Oncol 10, no. 2 (February 2012): 136–37.
       Link to Item
    • Farag, Sherif S., Kati Maharry, Mei-Jie Zhang, Waleska S. Pérez, Stephen L. George, Krzysztof Mrózek, John DiPersio, et al. “Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission..” Biol Blood Marrow Transplant 17, no. 12 (December 2011): 1796–1803. https://doi.org/10.1016/j.bbmt.2011.06.005.
       Full Text  Link to Item
    • Kelsey, Chris R., Mitchell E. Horwitz, Junzo P. Chino, Oana Craciunescu, Beverly Steffey, Rodney J. Folz, Nelson J. Chao, David A. Rizzieri, and Lawrence B. Marks. “Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors..” Int J Radiat Oncol Biol Phys 81, no. 3 (November 1, 2011): 812–18. https://doi.org/10.1016/j.ijrobp.2010.06.058.
       Full Text  Link to Item
    • Kanda, Junya, David A. Rizzieri, Cristina Gasparetto, Gwynn D. Long, John P. Chute, Keith M. Sullivan, Ashley Morris, et al. “Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning..” Biol Blood Marrow Transplant 17, no. 6 (June 2011): 867–74. https://doi.org/10.1016/j.bbmt.2010.09.009.
       Full Text  Link to Item
    • Palmer, J., T. Goggins, G. Broadwater, N. Chao, M. Horwitz, A. Beaven, K. Sullivan, R. E. Coleman, and D. Rizzieri. “Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma..” Bone Marrow Transplant 46, no. 6 (June 2011): 847–51. https://doi.org/10.1038/bmt.2010.203.
       Full Text  Link to Item
    • Advani, Anjali S., Sarah Gibson, Elizabeth Douglas, Julia Diacovo, Paul Elson, Matt Kalaycio, Ed Copelan, et al. “Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)..” Br J Haematol 153, no. 4 (May 2011): 504–7. https://doi.org/10.1111/j.1365-2141.2011.08607.x.
       Full Text  Link to Item
    • Kanda, Junya, Richard D. Lopez, and David A. Rizzieri. “Alemtuzumab for the prevention and treatment of graft-versus-host disease..” Int J Hematol 93, no. 5 (May 2011): 586–93. https://doi.org/10.1007/s12185-011-0802-2.
       Full Text  Link to Item
    • Wang, Endi, Charles Blake Hutchinson, Qin Huang, Chuanyi Mark Lu, Jennifer Crow, Frances F. Wang, Siby Sebastian, et al. “Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature..” American Journal of Clinical Pathology 135, no. 4 (April 2011): 525–40. https://doi.org/10.1309/ajcppjuq9dnr1ghp.
       Full Text
    • Craciunescu, Oana I., Beverly A. Steffey, Chris R. Kelsey, Nicole A. Larrier, Cathy J. Paarz-Largay, Robert G. Prosnitz, Nelson Chao, et al. “Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial..” Int J Radiat Oncol Biol Phys 79, no. 4 (March 15, 2011): 1248–55. https://doi.org/10.1016/j.ijrobp.2010.05.036.
       Full Text  Link to Item
    • Kanda, J., R. D. Lopez, and D. A. Rizzieri. “Alemtuzumab for the prevention and treatment of graft-versus-host disease.” International Journal of Hematology, 2011, 1–8.
    • Rizzieri, David A., Christopher Crout, Robert Storms, Jared Golob, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, et al. “Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors..” Cancer Invest 29, no. 1 (January 2011): 56–61. https://doi.org/10.3109/07357907.2010.535055.
       Full Text  Link to Item
    • Jima, Dereje D., Jenny Zhang, Cassandra Jacobs, Kristy L. Richards, Cherie H. Dunphy, William W. L. Choi, Wing Yan Au, et al. “Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs..” Blood 116, no. 23 (December 2, 2010): e118–27. https://doi.org/10.1182/blood-2010-05-285403.
       Full Text  Link to Item
    • Advani, Anjali S., Mazyar Shadman, Francis Ali-Osman, Andrew Barker, Lisa Rybicki, Matt Kalaycio, Mikkael A. Sekeres, et al. “A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse..” Clin Lymphoma Myeloma Leuk 10, no. 6 (December 2010): 473–76. https://doi.org/10.3816/CLML.2010.n.082.
       Full Text  Link to Item
    • Gupta, Vikas, Martin S. Tallman, Wensheng He, Brent R. Logan, Edward Copelan, Robert Peter Gale, Hanna J. Khoury, et al. “Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis..” Blood 116, no. 11 (September 16, 2010): 1839–48. https://doi.org/10.1182/blood-2010-04-278317.
       Full Text  Link to Item
    • Kanda, Junya, Nelson J. Chao, and David A. Rizzieri. “Haploidentical transplantation for leukemia..” Curr Oncol Rep 12, no. 5 (September 2010): 292–301. https://doi.org/10.1007/s11912-010-0113-4.
       Full Text  Link to Item
    • Duval, Michel, John P. Klein, Wensheng He, Jean-Yves Cahn, Mitchell Cairo, Bruce M. Camitta, Rammurti Kamble, et al. “Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure..” J Clin Oncol 28, no. 23 (August 10, 2010): 3730–38. https://doi.org/10.1200/JCO.2010.28.8852.
       Full Text  Link to Item
    • Rizzieri, David A., Robert Storms, Dong-Feng Chen, Gwynn Long, Yiping Yang, Daniel A. Nikcevich, Cristina Gasparetto, et al. “Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation..” Biol Blood Marrow Transplant 16, no. 8 (August 2010): 1107–14. https://doi.org/10.1016/j.bbmt.2010.02.018.
       Full Text  Link to Item
    • Marks, David I., Tao Wang, Waleska S. Pérez, Joseph H. Antin, Edward Copelan, Robert Peter Gale, Biju George, et al. “The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission..” Blood 116, no. 3 (July 22, 2010): 366–74. https://doi.org/10.1182/blood-2010-01-264077.
       Full Text  Link to Item
    • Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy..” Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.
       Full Text  Link to Item
    • Rizzieri, David, Samantha LoRusso, William Tse, Khuda Khan, Anjali Advani, Joseph Moore, Verena Karsten, Ann Cahill, and Stanton L. Gerson. “Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia..” Clin Lymphoma Myeloma Leuk 10, no. 3 (June 2010): 211–16. https://doi.org/10.3816/CLML.2010.n.033.
       Full Text  Link to Item
    • Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma..” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
       Full Text  Link to Item
    • Rao, Arati V., Peter J. M. Valk, Klaus H. Metzeler, Chaitanya R. Acharya, Sascha A. Tuchman, Marvaretta M. Stevenson, David A. Rizzieri, et al. “Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia..” J Clin Oncol 27, no. 33 (November 20, 2009): 5580–86. https://doi.org/10.1200/JCO.2009.22.2547.
       Full Text  Link to Item
    • Zhao, C., A. Chen, C. H. Jamieson, M. Fereshteh, A. Abrahamsson, J. Blum, H. Y. Kwon, et al. “Erratum: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia (Cancer Cell) (2008) 14 (238-249) DOI:10.1038/nature08255).” Nature 460, no. 7255 (July 30, 2009). https://doi.org/10.1038/nature08255.
       Full Text
    • Rizzieri, David A., Jenny A. O’Brien, Gloria Broadwater, Carlos M. Decastro, Prakash Dev, Louis Diehl, Anne Beaven, et al. “Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia..” Cancer 115, no. 13 (July 1, 2009): 2922–29. https://doi.org/10.1002/cncr.24379.
       Full Text  Link to Item
    • Nicolini, F. E., G. Alimena, H. K. Al-Ali, A. T. Turkina, Z. Shen, S. Jootar, G. Smith, et al. “EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS (PTS) WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): SUBGROUP ANALYSIS OF PATIENTS WHO FAILED PRIOR DASATINIB THERAPY.” Haematologica the Hematology Journal 94 (June 1, 2009): 257–257.
       Link to Item
    • Nicolini, F. E., G. Alimena, H. K. Al-Ali, A. T. Turkina, Z. Shen, S. Jootar, G. Smith, et al. “FINAL SAFETY ANALYSIS OF 1,793 CML PATIENTS FROM ENACT (EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA.” Haematologica the Hematology Journal 94 (June 1, 2009): 255–56.
       Link to Item
    • Prince, H Miles, Dirk Hönemann, Andrew Spencer, David A. Rizzieri, Edward A. Stadtmauer, Andrew W. Roberts, Nizar Bahlis, et al. “Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)..” Blood 113, no. 19 (May 7, 2009): 4819–20. https://doi.org/10.1182/blood-2009-02-207209.
       Full Text  Link to Item
    • Zhang, Jenny, Dereje D. Jima, Cassandra Jacobs, Randy Fischer, Eva Gottwein, Grace Huang, Patricia L. Lugar, et al. “Patterns of microRNA expression characterize stages of human B-cell differentiation..” Blood 113, no. 19 (May 7, 2009): 4586–94. https://doi.org/10.1182/blood-2008-09-178186.
       Full Text  Link to Item
    • Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70215-2.
       Full Text
    • Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P129 A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70210-3.
       Full Text
    • Shea, Thomas C., Anne W. Beaven, Dominic T. Moore, Jonathan S. Serody, Don A. Gabriel, Nelson Chao, Jon P. Gockerman, Reynaldo A. Garcia, and David A. Rizzieri. “Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival..” Leuk Lymphoma 50, no. 5 (May 2009): 741–48. https://doi.org/10.1080/10428190902853136.
       Full Text  Link to Item
    • Zhao, Chen, Alan Chen, Catriona H. Jamieson, Mark Fereshteh, Annelie Abrahamsson, Jordan Blum, Hyog Young Kwon, et al. “Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia..” Nature 458, no. 7239 (April 9, 2009): 776–79. https://doi.org/10.1038/nature07737.
       Full Text  Link to Item
    • Rizzieri, D. A., P. Dev, G. D. Long, C. Gasparetto, K. M. Sullivan, Ml Horwitz, J. Chute, and N. J. Chao. “Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors..” Bone Marrow Transplant 43, no. 4 (February 2009): 327–33. https://doi.org/10.1038/bmt.2008.321.
       Full Text  Link to Item
    • Weinberg, J. B., A. D. Volkheimer, M. Mihovilovic, N. Jiang, Y. Chen, K. Bond, J. O. Moore, et al. “Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia..” Leukemia 22, no. 12 (December 2008): 2184–92. https://doi.org/10.1038/leu.2008.241.
       Full Text  Link to Item
    • Allen, Steven L., Harry P. Erba, David A. Rizzieri, Margaret O’Donnell, Bayard Powell, Ante S. Lundberg, John M. Bennett, and Robert L. Capizzi. “Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.” Blood 112, no. 11 (November 16, 2008): 1019–20.
       Link to Item
    • Gasparet, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos De Castro, Joseph Moore, Gwynn D. Long, Mitchell Horwitz, et al. “Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.” Blood 112, no. 11 (November 16, 2008): 1142–1142.
       Link to Item
    • O’Brien, Susan, David A. Rizzieri, Norbert Vey, Hagop M. Kantarjian, Tove Flem Jacobsen, Bo I. Nilsson, Karin Staudacher, and Francis Giles. “A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies..” Blood 112, no. 11 (November 16, 2008): 350–350.
       Link to Item
    • Prasad, Vinod K., Dong-Feng Chen, Gloria Broadwater, Nancy L. Reinsmoen, Adella Clark, Nelson J. Chao, and David A. Rizzieri. “Differential Impact of Inhibitory and Activating Killer Ig-Like Receptors and HLA Ligand on Outcomes of Transplantation for Myeloid and Lymphoid Malignancies.” Blood 112, no. 11 (November 16, 2008): 1118–1118.
       Link to Item
    • Rao, Arati V., Sascha A. Tuchman, Anil Potti, David A. Rizzieri, Hiroyuki Mano, Ruud Delwel, Peter Valk, and B. Lowenberg. “Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.” Blood 112, no. 11 (November 16, 2008): 785–86.
       Link to Item
    • Rizzieri, Davd A., Robert Storms, Daniel Nikcevich, Bercedis Peterson, Debashish Misra, Christine Apple, Megan Baker, et al. “Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation.” Blood 112, no. 11 (November 16, 2008): 133–34.
       Link to Item
    • Zhang, Jenny, Dereje D. Jima, Cassandra L. Jacobs, Eva Gottwein, Grace Huang, Patricia L. Lugar, Anand S. Lagoo, David A. Rizzieri, Peter E. Lipsky, and Sandeep S. Dave. “MicroRNAs Regulate Mature B Cell Differentiation.” Blood 112, no. 11 (November 16, 2008): 262–262.
       Link to Item
    • Lee, Stephanie J., Manisha Kukreja, Tao Wang, Sergio A. Giralt, Jeffrey Szer, Mukta Arora, Ann E. Woolfrey, et al. “Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia..” Blood 112, no. 8 (October 15, 2008): 3500–3507. https://doi.org/10.1182/blood-2008-02-141689.
       Full Text  Link to Item
    • Rao, Arati V., Islam R. Younis, Gregory J. Sand, Ivan Spasojevic, David J. Adams, Carlos M. Decastro, John P. Gockerman, et al. “Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia..” Leuk Lymphoma 49, no. 8 (August 2008): 1523–29. https://doi.org/10.1080/10428190802210700.
       Full Text  Link to Item
    • Nicolini, F. E., G. Alimena, H. Al-Ali, A. Y. Zaritskey, Z. Shen, S. Jootar, G. Smith, Y. Hsu, M. L. Veronese, and D. A. Rizzieri. “Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): Updated safety analysis.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7059–7059. https://doi.org/10.1200/jco.2008.26.15_suppl.7059.
       Full Text
    • O’Brien, S. M., N. Vey, D. A. Rizzieri, H. M. Kantarjian, T. Prebet, F. Ravandi, T. F. Jacobsen, B. I. Nilsson, K. Staudacher, and F. J. Giles. “A phase I study with CP-4055 in patients with hematologic malignancies.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2532–2532. https://doi.org/10.1200/jco.2008.26.15_suppl.2532.
       Full Text
    • Rizzieri, D. A., H. P. Erba, M. O’Donnell, B. L. Powell, A. S. Lundberg, J. M. Bennett, and R. L. Capizzi. “Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7027–7027. https://doi.org/10.1200/jco.2008.26.15_suppl.7027.
       Full Text
    • Horwitz, Mitchell E., Ashley Morris, Cristina Gasparetto, Keith Sullivan, Gwynn Long, John Chute, David Rizzieri, Jackie McPherson, and Nelson Chao. “Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients..” Biol Blood Marrow Transplant 14, no. 5 (May 2008): 591–94. https://doi.org/10.1016/j.bbmt.2008.02.016.
       Full Text  Link to Item
    • Rizzieri, David A., Eric Feldman, John F. Dipersio, Nashat Gabrail, Wendy Stock, Roger Strair, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, and Francis J. Giles. “A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies..” Clin Cancer Res 14, no. 9 (May 1, 2008): 2756–62. https://doi.org/10.1158/1078-0432.CCR-07-1372.
       Full Text  Link to Item
    • Adams, David J., Marit L. Sandvold, Finn Myhren, Tove F. Jacobsen, Frank Giles, and David A. Rizzieri. “Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells..” Leuk Lymphoma 49, no. 4 (April 2008): 786–97. https://doi.org/10.1080/10428190801935752.
       Full Text  Link to Item
    • Frankel, Arthur, Jen-Sing Liu, David Rizzieri, and Donna Hogge. “Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia..” Leuk Lymphoma 49, no. 3 (March 2008): 543–53. https://doi.org/10.1080/10428190701799035.
       Full Text  Link to Item
    • Smith, Sonali M., David Grinblatt, Jeffrey L. Johnson, Donna Niedzwiecki, David Rizzieri, Nancy L. Bartlett, Bruce D. Cheson, and Bruce D. Cancer and Leukemia Group B. “Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B..” Br J Haematol 140, no. 3 (February 2008): 313–19. https://doi.org/10.1111/j.1365-2141.2007.06937.x.
       Full Text  Link to Item
    • Byrne, B. J., M. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. Chute, N. J. Chao, and D. A. Rizzieri. “Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection..” Bone Marrow Transplant 41, no. 1 (January 2008): 39–43. https://doi.org/10.1038/sj.bmt.1705882.
       Full Text  Link to Item
    • Hobeika, Ac, T. Osada, D. Serra, S. Peplinski, K. Hanson, Y. Tanaka, D. Niedzwiecki, et al. “Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease..” Cytotherapy 10, no. 3 (2008): 289–302. https://doi.org/10.1080/14653240801927040.
       Full Text  Link to Item
    • Horwitz, Mitchell E., Ivan Spasojevic, Ashley Morris, Marilyn Telen, James Essell, Cristina Gasparetto, Keith Sullivan, et al. “Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics..” Biol Blood Marrow Transplant 13, no. 12 (December 2007): 1422–26. https://doi.org/10.1016/j.bbmt.2007.08.050.
       Full Text  Link to Item
    • Weinberg, J Brice, Alicia D. Volkheimer, Youwei Chen, Bethany E. Beasley, Ning Jiang, Mark C. Lanasa, Daphne Friedman, et al. “Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia..” Am J Hematol 82, no. 12 (December 2007): 1063–70. https://doi.org/10.1002/ajh.20987.
       Full Text  Link to Item
    • Koh, Liang-Piu, David A. Rizzieri, and Nelson J. Chao. “Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors..” Biol Blood Marrow Transplant 13, no. 11 (November 2007): 1249–67. https://doi.org/10.1016/j.bbmt.2007.08.003.
       Full Text  Link to Item
    • Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, et al. “Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution..” J Clin Oncol 25, no. 6 (February 20, 2007): 690–97. https://doi.org/10.1200/JCO.2006.07.0953.
       Full Text  Link to Item
    • Giles, Francis, David Rizzieri, Judith Karp, Norbert Vey, Farhad Ravandi, Stefan Faderl, Khuda Dad Khan, et al. “Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia..” J Clin Oncol 25, no. 1 (January 1, 2007): 25–31. https://doi.org/10.1200/JCO.2006.07.0961.
       Full Text  Link to Item
    • Lagoo, Anand S., Jerald Z. Gong, Timothy T. Stenzel, Barbara K. Goodman, Patrick J. Buckley, Nelson J. Chao, Cristina Gasparetto, Gwynn D. Long, and David A. Rizzieri. “Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment..” Arch Pathol Lab Med 130, no. 10 (October 2006): 1479–88. https://doi.org/10.1043/1543-2165(2006)130[1479:MEOSBM]2.0.CO;2.
       Full Text  Link to Item
    • Schiller, Gary J., James Slack, John D. Hainsworth, James Mason, Mansoor Saleh, David Rizzieri, Dan Douer, and Alan F. List. “Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes..” J Clin Oncol 24, no. 16 (June 1, 2006): 2456–64. https://doi.org/10.1200/JCO.2005.03.7903.
       Full Text  Link to Item
    • Vredenburgh, James J., David Coniglio, Gloria Broadwater, Roy B. Jones, Maureen Ross, Elizabeth J. Shpall, Atif Hussein, et al. “Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone..” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 12, no. 2 (February 2006): 195–203. https://doi.org/10.1016/j.bbmt.2005.10.009.
       Full Text
    • Dannull, Jens, Zhen Su, David Rizzieri, Benjamin K. Yang, Doris Coleman, Donna Yancey, Aijing Zhang, et al. “Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells..” J Clin Invest 115, no. 12 (December 2005): 3623–33. https://doi.org/10.1172/JCI25947.
       Full Text  Link to Item
    • Rizzieri, David A., Martha Wadleigh, Carol J. Wikstrand, Karen P. Mann, Filiz Sen, Bercedis L. Peterson, Donna Niedzwiecki, Alan D. Proia, and Darell D. Bigner. “Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity..” Leuk Lymphoma 46, no. 10 (October 2005): 1455–62. https://doi.org/10.1080/10428190500158060.
       Full Text  Link to Item
    • Rao, Arati V., Gamal Akabani, and David A. Rizzieri. “Radioimmunotherapy for Non-Hodgkin's Lymphoma..” Clin Med Res 3, no. 3 (August 2005): 157–65.
       Link to Item
    • Shanks, Ryan H., David A. Rizzieri, James L. Flowers, O Michael Colvin, and David J. Adams. “Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia..” Clin Cancer Res 11, no. 11 (June 1, 2005): 4225–33. https://doi.org/10.1158/1078-0432.CCR-04-2106.
       Full Text  Link to Item
    • Chao, Nelson. “Hematopoietic stem cell transplantation..” Curr Opin Hematol 11, no. 6 (November 2004): 373–74.
       Link to Item
    • Nieto, Yago, James J. Vredenburgh, Elizabeth J. Shpall, Scott I. Bearman, Peter A. McSweeney, Nelson Chao, David Rizzieri, et al. “Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer..” Clin Cancer Res 10, no. 21 (November 1, 2004): 7136–43. https://doi.org/10.1158/1078-0432.CCR-04-0891.
       Full Text  Link to Item
    • Gasparetto, Maura, Tracy Gentry, Said Sebti, Erica O’Bryan, Ramadevi Nimmanapalli, Michelle A. Blaskovich, Kapil Bhalla, et al. “Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening..” J Immunol Methods 292, no. 1–2 (September 2004): 59–71. https://doi.org/10.1016/j.jim.2004.06.003.
       Full Text  Link to Item
    • Talbot, Jeffrey, Valerie K. Ibom, David A. Rizzieri, Robert Barrier, Donna Niedzwieki, Carlos M. DeCastro, Joseph O. Moore, et al. “Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma..” Clin Lymphoma 5, no. 2 (September 2004): 116–22.
       Link to Item
    • Bhagat, Rajesh, David A. Rizzieri, James J. Vredenburgh, Nelson J. Chao, and Rodney J. Folz. “Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?.” Chest 126, no. 2 (August 2004): 642–44. https://doi.org/10.1378/chest.126.2.642.
       Full Text  Link to Item
    • Chao, Nelson J., Liang-Piu Koh, Gwynn D. Long, Cristina Gasparetto, Mitchell Horwitz, Ashley Morris, Martha Lassiter, Keith M. Sullivan, and David A. Rizzieri. “Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens..” Biol Blood Marrow Transplant 10, no. 8 (August 2004): 569–75. https://doi.org/10.1016/j.bbmt.2004.05.001.
       Full Text  Link to Item
    • Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma..” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.
       Full Text  Link to Item
    • Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma..” Cancer 100, no. 11 (June 1, 2004): 2408–14. https://doi.org/10.1002/cncr.20245.
       Full Text  Link to Item
    • Snyder, Matthew J., Timothy T. Stenzel, Patrick J. Buckley, Anand S. Lagoo, David A. Rizzieri, Cristina Gasparetto, James J. Vredenburgh, Nelson J. Chao, and Jerald Z. Gong. “Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation..” Am J Surg Pathol 28, no. 6 (June 2004): 794–800.
       Link to Item
    • Rizzieri, David A., Jeffrey L. Johnson, Donna Niedzwiecki, Edward J. Lee, James W. Vardiman, Bayard L. Powell, Maurice Barcos, et al. “Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251..” Cancer 100, no. 7 (April 1, 2004): 1438–48. https://doi.org/10.1002/cncr.20143.
       Full Text  Link to Item
    • Goggins, Timothy F., and David R. Rizzieri. “Nonmyeloablative allogeneic stem cell transplantation using alternative donors..” Cancer Control 11, no. 2 (March 2004): 86–96. https://doi.org/10.1177/107327480401100215.
       Full Text  Link to Item
    • Ghobrial, Irene M., Larry A. Otteman, and William L. White. “An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab..” N Engl J Med 349, no. 26 (December 25, 2003): 2570–72. https://doi.org/10.1056/NEJM200312253492622.
       Full Text  Link to Item
    • Rizzieri, D. A., S. Weitman, and D. M. Vaughn. “An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.” New England Journal of Medicine 349, no. 26 (December 25, 2003): 2571–72.
       Link to Item
    • Long, Gwynn D., Mary Laughlin, Bella Madan, Joanne Kurtzberg, Cristina Gasparetto, Ashley Morris, David Rizzieri, et al. “Unrelated umbilical cord blood transplantation in adult patients..” Biol Blood Marrow Transplant 9, no. 12 (December 2003): 772–80. https://doi.org/10.1016/j.bbmt.2003.08.007.
       Full Text  Link to Item
    • Ibom, Valerie K., Robert G. Prosnitz, Jerald Z. Gong, Joseph O. Moore, Carlos M. DeCastro, Leonard R. Prosnitz, David A. Rizzieri, and Jon P. Gockerman. “Rituximab in lymphocyte predominance Hodgkin's disease: a case series..” Clin Lymphoma 4, no. 2 (September 2003): 115–18.
       Link to Item
    • Talbot, Jeffrey, David A. Rizzieri, Carlos M. DeCastro, Joseph O. Moore, Patrick Buckley, Rhonda Laney, Diane Stevenson, Heather Brumbaugh, and Jon P. Gockerman. “High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series..” Am J Hematol 73, no. 4 (August 2003): 295–96. https://doi.org/10.1002/ajh.10362.
       Full Text  Link to Item
    • Gong, Jerald Z., Timothy T. Stenzel, Ellen R. Bennett, Anand S. Lagoo, Cherie H. Dunphy, Joseph O. Moore, David A. Rizzieri, James H. Tepperberg, Peter Papenhausen, and Patrick J. Buckley. “Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases..” Am J Surg Pathol 27, no. 6 (June 2003): 818–27.
       Link to Item
    • Rizzieri, David A., Jeffrey T. Talbot, Gwynn D. Long, James J. Vredenburgh, Christina Gasparetto, Clayton S. Smith, Michael O. Colvin, et al. “4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia..” Biol Blood Marrow Transplant 9, no. 3 (March 2003): 183–88. https://doi.org/10.1053/bbmt.2003.50011.
       Full Text  Link to Item
    • Rizzieri, David A., Valerie K. Ibom, Joseph O. Moore, Carlos M. DeCastro, Gary L. Rosner, David J. Adams, Traci Foster, et al. “Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia..” Clin Cancer Res 9, no. 2 (February 2003): 663–68.
       Link to Item
    • Morse, Michael A., David Rizzieri, Timothy T. Stenzel, Amy C. Hobeika, James J. Vredenburgh, Nelson J. Chao, Timothy M. Clay, Paul J. Mosca, and H Kim Lyerly. “Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants..” J Hematother Stem Cell Res 11, no. 4 (August 2002): 659–68. https://doi.org/10.1089/15258160260194802.
       Full Text  Link to Item
    • Bass, Adam J., Jon P. Gockerman, Eve Hammett, Carlos M. DeCastro, David J. Adams, Gary L. Rosner, Nancy Payne, et al. “Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma..” J Clin Oncol 20, no. 13 (July 1, 2002): 2995–3000. https://doi.org/10.1200/JCO.2002.08.166.
       Full Text  Link to Item
    • McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia..” Leuk Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.
       Full Text  Link to Item
    • Gasparetto, Cristina, Maura Gasparetto, Michael Morse, Barbara Rooney, James J. Vredenburgh, Gwynn D. Long, David A. Rizzieri, Jennifer Loftis, Nelson J. Chao, and Clay Smith. “Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF..” Cytokine 18, no. 1 (April 7, 2002): 8–19.
       Link to Item
    • Chao, N. J., D. A. Rizzieri, G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, and P. Davis. “Allogeneic engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen.” Leukemia 16, no. 3 (March 1, 2002): 407–407.
       Link to Item
    • Bass, Adam J., Jerald Gong, Ramona Nelson, and David A. Rizzieri. “CD52 expression in mantle cell lymphoma..” Leuk Lymphoma 43, no. 2 (February 2002): 339–42. https://doi.org/10.1080/10428190290006125.
       Full Text  Link to Item
    • Rizzieri, David A., Adam J. Bass, Gary L. Rosner, Jon P. Gockerman, Carlos M. DeCastro, William P. Petros, David J. Adams, et al. “Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia..” J Clin Oncol 20, no. 3 (February 1, 2002): 674–79. https://doi.org/10.1200/JCO.2002.20.3.674.
       Full Text  Link to Item
    • Chao, Nelson J., Cong X. Liu, Barbara Rooney, Benny J. Chen, Gwynn D. Long, James J. Vredenburgh, Ashley Morris, Cristina Gasparetto, and David A. Rizzieri. “Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells..” Biol Blood Marrow Transplant 8, no. 5 (2002): 249–56.
       Link to Item
    • Stuart, Monic J., William P. Peters, Gloria Broadwater, Atif Hussein, Maureen Ross, Lawrence B. Marks, Rodney J. Folz, et al. “High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes..” Biol Blood Marrow Transplant 8, no. 12 (2002): 666–73.
       Link to Item
    • Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, T. T. Stenzel, P. Davis, and N. J. Chao. “Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen..” Blood 98, no. 12 (December 1, 2001): 3486–88. https://doi.org/10.1182/blood.v98.12.3486.
       Full Text  Link to Item
    • Bass, A., J. O. Moore, C. DeCastro, J. P. Gockerman, G. Rosner, N. Payne, T. Foster, et al. “Prolonged infusion gemcitabine in combination with CPT-11 for relapsed or refractory hematologic malignancies..” Blood 98, no. 11 (November 16, 2001): 209B-209B.
       Link to Item
    • Gandy, K. L., N. J. Chao, C. Gasparetto, G. D. Long, N. L. Reinsmoen, and D. A. Rizzieri. “PRA reduction after sublethal preconditioning and hematopoietic reconstitution with Campath-1-treated mobilized peripheral blood..” Blood 98, no. 11 (November 16, 2001): 315B-315B.
       Link to Item
    • Guzman, M. L., S. J. Neering, C. Swiderski, B. Grimes, D. S. Howard, D. A. Rizzieri, and C. T. Jordan. “Unique molecular characteristics of primitive human AML cells permit apoptosis to be specifically induced in leukemic but not normal stem cells..” Blood 98, no. 11 (November 16, 2001): 93A-93A.
       Link to Item
    • Klein, A. K., M. B. Qumsiyeh, N. Hayes, G. D. Long, J. J. Vredenburgh, D. A. Rizzieri, C. Gasparetto, and N. J. Chao. “Translocations of the MLL gene can be detected in an increased proportion of mononuclear cells collected after etoposide priming in patients subsequently developing secondary acute leukemia..” Blood 98, no. 11 (November 16, 2001): 401A-402A.
       Link to Item
    • Lagoo, A. S., J. Z. Gong, D. A. Rizzieri, T. T. Stenzel, N. J. Chao, and P. J. Buckley. “Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow..” Blood 98, no. 11 (November 16, 2001): 185A-185A.
       Link to Item
    • McCune, S. L., J. P. Gockerman, J. O. Moore, C. M. deCastro, A. J. Bass, N. J. Chao, G. D. Long, et al. “Alemtuzumab (Campath) in relapsed or refractory CLL or PLL..” Blood 98, no. 11 (November 16, 2001): 290B-291B.
       Link to Item
    • Rizzieri, D. A., C. DeCastro, J. P. Gockerman, D. Niedzwiecki, J. J. Vredenburgh, C. Gasparetto, G. Long, et al. “Low dose, weekly, paclitaxel as salvage therapy for non-Hodgkins lymphoma (NHL)..” Blood 98, no. 11 (November 16, 2001): 246B-246B.
       Link to Item
    • Rizzieri, D. A., G. Akabani, R. E. Coleman, M. R. Zalutsky, D. Niedzwiecki, N. Payne, C. Wikstrand, and D. D. Bigner. “Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL)..” Blood 98, no. 11 (November 16, 2001): 247B-247B.
       Link to Item
    • Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, D. Niedzwiecki, M. Lassiter, et al. “Durable engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen for adults..” Blood 98, no. 11 (November 16, 2001): 185A-185A.
       Link to Item
    • Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, M. Lassiter, J. Loftis, et al. “Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells..” Blood 98, no. 11 (November 16, 2001): 420A-421A.
       Link to Item
    • Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, M. Lassiter, J. Loftis, et al. “Non-myeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells..” Blood 98, no. 11 (November 16, 2001): 669A-669A.
       Link to Item
    • Rizzieri, D. A., J. P. Gockerman, J. O. Moore, C. DeCastro, G. D. Long, J. J. Vredenburgh, D. Niedzwiecki, et al. “Dose dense, high intensity therapy for mantle cell lymphoma..” Blood 98, no. 11 (November 16, 2001): 681A-682A.
       Link to Item
    • Rizzieri, D. A., V. Ibom, C. DeCastro, J. O. Moore, N. Payne, D. Adams, D. J. Adams, et al. “Phase I trial of prolonged infusion gemcitabine with fludarabine for relapsed/refractory acute leukemia..” Blood 98, no. 11 (November 16, 2001): 220B-221B.
       Link to Item
    • Wadleigh, M., D. Niedzwiecki, P. Davis, N. Payne, F. Sen, K. P. Mann, A. Proia, D. Hollis, and D. A. Rizzieri. “Increased microvessel density in non-Hodgkin's lymphoma (NHL) is localized to the site of disease changes in accordance with disease response..” Blood 98, no. 11 (November 16, 2001): 236B-236B.
       Link to Item
    • Guzman, M. L., S. J. Neering, D. Upchurch, B. Grimes, D. S. Howard, D. A. Rizzieri, S. M. Luger, and C. T. Jordan. “Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells..” Blood 98, no. 8 (October 15, 2001): 2301–7. https://doi.org/10.1182/blood.v98.8.2301.
       Full Text  Link to Item
    • McCune, S. L., J. P. Gockerman, and D. A. Rizzieri. “Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma..” Jama 286, no. 10 (September 12, 2001): 1149–52. https://doi.org/10.1001/jama.286.10.1149.
       Full Text  Link to Item
    • Laughlin, M. J., J. Barker, B. Bambach, O. N. Koc, D. A. Rizzieri, J. E. Wagner, S. L. Gerson, et al. “Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors..” N Engl J Med 344, no. 24 (June 14, 2001): 1815–22. https://doi.org/10.1056/NEJM200106143442402.
       Full Text  Link to Item
    • Guzman, M. L., D. Upchurch, B. Grimes, D. S. Howard, D. A. Rizzieri, S. M. Luger, G. L. Phillips, and C. T. Jordan. “Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells..” Blood 97, no. 7 (April 1, 2001): 2177–79. https://doi.org/10.1182/blood.v97.7.2177.
       Full Text  Link to Item
    • Gong, J. Z., A. S. Lagoo, D. A. Rizzieri, T. T. Stenzel, N. J. Chao, and P. J. Buckley. “Serial morphologic changes in the bone arrow after non-myeloablative allogenic "mini-allogenic" stem cell transplant (NMASCT): correlation with engraftment..” Laboratory Investigation 81, no. 1 (January 1, 2001): 164A-164A.
       Link to Item
    • Gong, J. Z., A. S. Lagoo, D. A. Rizzieri, T. T. Stenzel, N. J. Chao, and P. J. Buckley. “Serial morphologic changes in the bone marrow after nonmyeloablative allogenic "mini-allogenic" stem cell transplant (NMASCT): correlation with engraftment..” Modern Pathology 14, no. 1 (January 1, 2001): 164A-164A.
       Link to Item
    • McGaughey, D. S., D. A. Nikcevich, G. D. Long, J. J. Vredenburgh, D. Rizzieri, C. A. Smith, G. Broadwater, et al. “Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation..” Biol Blood Marrow Transplant 7, no. 5 (2001): 274–78.
       Link to Item
    • Rizzieri, D. A., J. P. Gockerman, C. M. Decastro, S. Lilly, and T. Foster. “Phase i trial of continuously infused gemcitabine with cpt-11 for refractory hematologic malignancies.” Blood 96, no. 11 PART II (December 1, 2000).
    • Guzman, H. L., D. Upchurch, B. Grimes, D. S. Howard, G. L. Phillips, D. A. Rizzieri, S. M. Luger, and C. T. Jordan. “Induction of apoptosis in primitive human AML cells using the proteasome inhibitor MG-132 and/or sodium salicylate..” Blood 96, no. 11 (November 16, 2000): 80A-80A.
       Link to Item
    • Guzman, M. L., D. Upchurch, B. Grimes, D. S. Howard, G. L. Phillips, D. A. Rizzieri, S. M. Luger, and C. T. Jordan. “Expression of tumor suppressor genes IRF-1 and DAP-kinase in primitive AML cells..” Blood 96, no. 11 (November 16, 2000): 696A-696A.
       Link to Item
    • Laughlin, M. J., J. Barker, B. Bambach, O. N. Koc, D. A. Rizzieri, J. E. Wagner, S. L. Gerson, et al. “Hematopoietic engraftment and survival after unrelated donor umbilical cord blood (UCB) transplantation in adult recipients..” Blood 96, no. 11 (November 16, 2000): 587A-+.
       Link to Item
    • Rizzieri, D. A., G. D. Long, C. Gasparetto, C. S. Smith, J. J. Vredenburgh, A. K. Morris, W. P. Petros, et al. “Phase I trial of escalting doses of 4-hydroxycyclophosphamide (4HC) purged autologous peripheral blood progenitor cells (PBPC) for leukemia..” Blood 96, no. 11 (November 16, 2000): 385A-385A.
       Link to Item
    • Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, C. S. Smith, A. K. Morris, W. P. Petros, et al. “Chimerism mediated immunotherapy using Campath T cell depleted peripheral blood progenitor cells (PBPC) with nonablative therapy provides reliable, durable allogeneic engraftment..” Blood 96, no. 11 (November 16, 2000): 521A-521A.
       Link to Item
    • Rizzieri, D. A., J. P. Gockerman, C. M. DeCastro, W. P. Petros, S. Lilly, P. H. Davis, T. Foster, et al. “Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia..” Blood 96, no. 11 (November 16, 2000): 326A-326A.
       Link to Item
    • Rizzieri, D. A., J. P. Gockerman, C. M. Decastro, S. Lilly, T. Foster, D. Adams, and J. O. Moore. “Phase I trial of continuously infused gemcitabine with CPT-11 for refractory hematologic malignancies..” Blood 96, no. 11 (November 16, 2000): 216B-216B.
       Link to Item
    • Elconin, J. H., K. B. Roberts, D. A. Rizzieri, C. Vermont, R. W. Clough, C. Kim, R. K. Dodge, and L. R. Prosnitz. “Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy..” Int J Radiat Oncol Biol Phys 48, no. 4 (November 1, 2000): 1097–1105. https://doi.org/10.1016/s0360-3016(00)00695-7.
       Full Text  Link to Item
    • Jordan, C. T., D. Upchurch, S. J. Szilvassy, M. L. Guzman, D. S. Howard, A. L. Pettigrew, T. Meyerrose, et al. “The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells..” Leukemia 14, no. 10 (October 2000): 1777–84.
       Link to Item
    • Jordan, C. T., D. A. Rizzieri, D. Upchurch, B. Grimes, and G. L. Phillips. “The interleukin-3 receptor alpha chain is highly expressed on primitive acute myelogenous leukemia cells..” Blood 94, no. 10 (November 15, 1999): 67A-67A.
       Link to Item
    • Jordan, C. T., G. L. Phillips, D. A. Rizzieri, S. M. Luger, B. Grimes, and D. Upchurch. “Cell cycle analyses and apoptosis in primitive leukemic and normal cells..” Blood 94, no. 10 (November 15, 1999): 687A-687A.
       Link to Item
    • Howard, D. S., D. A. Rizzierri, B. Grimes, D. Upchurch, G. L. Phillips, A. K. Stewart, J. R. Yannelli, and C. T. Jordan. “Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer..” Leukemia 13, no. 10 (October 1999): 1608–16.
       Link to Item
    • Rizzieri, D. A., J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, et al. “Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support..” J Clin Oncol 17, no. 10 (October 1999): 3064–74. https://doi.org/10.1200/JCO.1999.17.10.3064.
       Full Text  Link to Item
    • Rizzieri, D. A., J. J. Vredenburgh, N. J. Chao, G. Broadwater, D. Berry, and W. P. Peters. “Long term disease free survival for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose therapy with hematopoietic support..” Blood 92, no. 10 (November 15, 1998): 323A-323A.
       Link to Item
    • Rizzieri, D. A., J. J. Vredenburgh, N. J. Chao, G. Broadwater, D. Berry, and W. P. Peters. “Prognostic factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose therapy with hematopoietic support..” Blood 92, no. 10 (November 15, 1998): 462A-463A.
       Link to Item
    • Laughlin, M. J., D. A. Rizzieri, C. A. Smith, J. O. Moore, S. Lilly, D. McGaughey, P. Martin, et al. “Hematologic engraftment and reconstitution of immune function post unrelated placental cord blood transplant in an adult with acute lymphocytic leukemia..” Leuk Res 22, no. 3 (March 1998): 215–19.
       Link to Item
    • Laughlin, M. J., D. S. McGaughey, J. R. Crews, N. J. Chao, D. Rizzieri, M. Ross, J. Gockerman, et al. “Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant..” J Clin Oncol 16, no. 3 (March 1998): 1008–12. https://doi.org/10.1200/JCO.1998.16.3.1008.
       Full Text  Link to Item
    • Kurtzberg, J., M. J. Laughlin, C. A. Smith, D. A. Rizzieri, J. J. Vredenburgh, M. E. Lassiter, M. L. Affronti, et al. “Hematopoietic recovery in adult recipients following unrelated umbilical cord blood (UCB) transplantation..” Blood 90, no. 10 (November 15, 1997): 480–480.
       Link to Item
    • Rizzieri, D. A., and N. J. Chao. “Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support..” Curr Opin Oncol 9, no. 5 (September 1997): 420–27.
       Link to Item
    • Rizzieri, D. A., J. Liu, D. Miralles, and S. T. Traweek. “Kaposi's-sarcoma-associated herpesvirus is detected in peripheral blood mononuclear cells of HIV-infected homosexuals more often than in heterosexuals..” Cancer J Sci Am 3, no. 3 (May 1997): 153–56.
       Link to Item
    • Rizzieri, David A. “Thrombocytosis Associated with Low-Molecular-Weight Heparin.” Annals of Internal Medicine 126, no. 9 (May 1, 1997): 742–742. https://doi.org/10.7326/0003-4819-126-9-199705010-00025.
       Full Text
    • Williams, E. “Thrombocytosis associated with low-molecular-weight heparin..” Ann Intern Med 126, no. 9 (May 1, 1997): 742–43. https://doi.org/10.7326/0003-4819-126-9-199705010-00024.
       Full Text  Link to Item
    • Rizzieri, D. A., J. Liu, S. T. Traweek, and G. D. Miralles. “Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor..” Lancet 349, no. 9054 (March 15, 1997): 775–76. https://doi.org/10.1016/S0140-6736(05)60200-0.
       Full Text  Link to Item
    • Rizzieri, D. A., J. Liu, D. Miralles, and S. T. Traweek. “Increased prevalence of Kaposi's sarcoma-associated herpesvirus in peripheral blood mononuclear cells of HIV-infected homosexuals..” Blood 88, no. 10 (November 15, 1996): 1992–1992.
       Link to Item
    • Rizzieri, D. A., W. M. Wong, and J. P. Gockerman. “Thrombocytosis associated with low-molecular-weight heparin..” Ann Intern Med 125, no. 2 (July 15, 1996). https://doi.org/10.7326/0003-4819-125-2-199607150-00031.
       Full Text  Link to Item
    • Rizzieri, D. A., C. M. DeCastro, K. P. Mann, and J. O. Moore. “T cell lymphoblastic leukemia with mediastinal mass and c-kit expression..” Blood 86, no. 10 (November 15, 1995): 3095–3095.
       Link to Item
    • Rizzieri, D. A. “Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia..” Mayo Clin Proc 70, no. 5 (May 1995): 473–76. https://doi.org/10.4065/70.5.473.
       Full Text  Link to Item
    • Rizzieri, D. A. “Causes of Rhabdomyolysis: In response.” Mayo Clinic Proceedings 70, no. 12 (January 1, 1995). https://doi.org/10.4065/70.12.1225-b.
       Full Text

  • Book Sections

    • Koh, L. P., D. A. Rizzieri, and N. J. Chao. “Hematopoietic stem cell transplantation across genetic barriers using a nonmyeloablative conditioning regimen.” In Bone Marrow Transplantation Across Major Genetic Barriers, 1–492, 2010. https://doi.org/10.1057/9789814271271_0006.
       Full Text

  • Conference Papers

    • Atallah, Ehab L., Johnnie J. Orozco, Michael Craig, Moshe Yair Levy, Laura E. Finn, Sharif S. Khan, Alexander E. Perl, et al. “A Phase 2 Study of Actinium-225 (Ac-225)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 mu ci/Kg/Dose.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-111951.
       Full Text  Link to Item
    • Cook, Rachel J., Tamara Moyo, Jane L. Liesveld, David A. Rizzieri, Eytan M. Stein, Stephane De Botton, Gail J. Roboz, et al. “Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-111285.
       Full Text  Link to Item
    • Jacobs, Kenneth, Cedric Viero, John Godwin, Jan Baughman, Jichao Sun, Kang Ying, John Muth, et al. “Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart (R) Molecule for T-Cell Redirected Therapy.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-112615.
       Full Text  Link to Item
    • Pemmaraju, Naveen, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-118966.
       Full Text  Link to Item
    • Sorror, Mohamed L., Barry E. Storer, Aaron T. Gerds, Bruno C. Medeiros, Paul J. Shami, John P. Galvin, Kehinde U. Adekola, et al. “Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-112672.
       Full Text  Link to Item
    • Sorror, Mohamed L., Barry E. Storer, Aaron T. Gerds, Bruno C. Medeiros, Paul J. Shami, John P. Galvin, Kehinde U. Adekola, et al. “Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-113094.
       Full Text  Link to Item
    • Uy, Geoffrey L., Michael P. Rettig, Norbert Vey, John Godwin, Matthew C. Foster, David A. Rizzieri, Martha L. Arellano, et al. “Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart (R) Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-117085.
       Full Text  Link to Item
    • Ying, Zhitao, Li Long, Hong Liu, Yuqin Song, David A. Rizzieri, Bijan Nejadnik, Jun Zhu, and Cheng Liu. “ET190L1-Artemis (TM) Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-113163.
       Full Text  Link to Item
    • Cerdena, Sebastian, Melissa C. Mackey, Maragatha Kuchibhatla, David A. Rizzieri, and Meredith T. Moorman. “Evaluation of Residual Disease Positivity Rates in Adult Acute Lymphoblastic Leukemia Patients Treated with Asparaginase Versus Non-Asparaginase Containing Regimens.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
       Link to Item
    • Jurcic, Joseph G., Azra Raza, George Vlad, Eytan M. Stein, Mikhail Roshal, Dale L. Bixby, Daniel F. Boyer, et al. “Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
       Link to Item
    • Sung, Anthony D., Carlos M. de Castro, Thomas W. LeBlanc, Gwynn D. Long, Donna B. Adams, Danielle M. Brander, Sandeep Dave, et al. “Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
       Link to Item
    • Anand, Sarah, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Gwynn D. Long, Richard Lopez, Ashley K. Morris, et al. “Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning..” In Biol Blood Marrow Transplant, 23:1949–54, 2017. https://doi.org/10.1016/j.bbmt.2017.06.027.
       Full Text  Link to Item
    • Anand, Sarah, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Richard Lopez, Gwynn D. Long, Ashley K. Morris, et al. “Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning.” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Daver, Naval, Hagop M. Kantarjian, Gail J. Roboz, Patricia L. Kropf, Karen W. L. Yee, Casey L. O’Connell, Elizabeth A. Griffiths, et al. “Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia(r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies.” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Garcia-Manero, Guillermo, Megan Othus, John M. Pagel, Jerald P. Radich, Min Fang, David A. Rizzieri, Guido Marcucci, et al. “SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Lane, Andrew A., Kendra L. Sweet, Eunice S. Wang, William B. Donnellan, Roland B. Walter, Anthony S. Stein, David A. Rizzieri, et al. “Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD).” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Pagel, John M., Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P. Radich, David A. Rizzieri, Guido Marcucci, et al. “Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat.” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Pemmaraju, Naveen, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Poe, Jonathan C., Wei Jia, Hsuan Su, Zhiguo Li, Frances T. Hakim, Steven Z. Pavletic, Jeremy J. Rose, et al. “All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients.” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Skamene, Tanya, Wenyu Jiang, Ralph M. Meyer, Michael Crump, John Kuruvilla, C Tom Kouroukis, Stefano Luminari, et al. “Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.” In Blood, Vol. 128. AMER SOC HEMATOLOGY, 2016.
       Link to Item
    • Stephens, Sarah J., Samantha Thomas, David A. Rizzieri, Mitchell E. Horwitz, Nelson J. Chao, Ashley M. Engemann, Martha Lassiter, and Chris R. Kelsey. “Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity..” In Adv Radiat Oncol, 1:272–80, 2016. https://doi.org/10.1016/j.adro.2016.07.001.
       Full Text  Open Access Copy  Link to Item
    • Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn D. Long, David A. Rizzieri, Mitchell E. Horwitz, et al. “Efficacy of Autologous Stem Cell Transplantation in Older Multiple Myeloma Patients.” In Biology of Blood and Marrow Transplantation, 22:S223–S223. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.626.
       Full Text
    • Muffly, Lori, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud D. Aljurf, et al. “Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes.” In Biology of Blood and Marrow Transplantation, 22:S68–69. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.360.
       Full Text
    • Rizzieri, David A., Arati V. Rao, Anne Beaven, Danielle Brander, Carlos DeCastro, Louis Diehl, Thomas W. LeBlanc, et al. “Clinical and Immunomodulatiory Outcomes of Microtransplantation for AML.” In Biology of Blood and Marrow Transplantation, 22:S207–8. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.602.
       Full Text
    • Advani, Anjali S., William Tse, Xuefei Jia, Paul Elson, Brenda Cooper, Francis Ali-Osman, Jino Park, et al. “Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Berdeja, Jesus G., Michael Heinrich, Shaker Dakhil, Stuart L. Goldberg, Martha Wadleigh, Rosalind Catchatourian, Philip Kuriakose, et al. “ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Gasparetto, Cristina, Michael Green, Anandgopal Srinivasan, Yubin Kang, David A. Rizzieri, Carlos Decastro, Louis F. Diehl, et al. “A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma..” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Poe, Jonathan C., Wei Jia, Zhiguo Li, Frances T. Hakim, Steven Z. Pavletic, Jeremy J. Rose, David A. Rizzieri, et al. “Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Stein, Eytan M., Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Mojca Jongen-Lavrencic, Jessica K. Altman, et al. “A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Sweet, Kendra L., Naveen Pemmaraju, Andrew A. Lane, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Brander, Danielle M., Sallie D. Allgood, David A. Rizzieri, Tiffany Stewart, J Brice Weinberg, and Mark C. Lanasa. “Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL).” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
       Link to Item
    • Mauro, Michael J., Shaker Dakhil, Jorge E. Cortes, David A. Rizzieri, Christopher H. Keir, Sandy Yi, Michael C. Heinrich, et al. “Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
       Link to Item
    • Lim, Sharon, Tzuen Yih Saw, Min Zhang, Matthew R. Janes, Kassoum Nacro, Jeffrey Hill, An Qi Lim, et al. “Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function..” In Proc Natl Acad Sci U S A, 110:E2298–2307, 2013. https://doi.org/10.1073/pnas.1301838110.
       Full Text  Link to Item
    • Advani, Anjali, Brenda Cooper, Olumuyiwa Sowunmi, Paul Elson, Francis Ali-Osman, Jino Park, Arati Rao, et al. “A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML).” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Brander, Danielle M., Anne W. Beaven, Jon P. Gockerman, Louis F. Diehl, Cristina Gasparetto, Thomas C. Shea, Carlos deCastro, Joseph O. Moore, and David A. Rizzieri. “Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Kantarjian, Hagop M., Gail J. Roboz, David A. Rizzieri, Wendy Stock, Casey L. O’Connell, Elizabeth A. Griffiths, Karen Yee, et al. “Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Konopleva, Marina, Donna E. Hogge, David A. Rizzieri, Thomas P. Cirrito, Steven M. Kornblau, Gautam Borthakur, Carol Bivins, et al. “SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Love, Cassandra L., Dereje Jima, Zhen Sun, Rodney R. Miles, Cherie H. Dunphy, William W. L. Choi, Wing Y. Au, et al. “ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Rao, Arati, David A. Rizzieri, Eduardo Vanegas, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Donna Adams, Julie Warzecho, and Carlos Decastro. “Pilot Study of Sorafenib for Myelodysplastic Syndrome.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Rao, Arati, Ghazi Khan, David A. Rizzieri, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Anne W. Beaven, Donna Adams, Julie Warzecho, and Carlos Decastro. “Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Rizzieri, David A., Norbert Vey, Xavier Thomas, Francoise Huguet, Richard F. Schlenk, Juergen Krauter, Thomas Kindler, et al. “A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
       Link to Item
    • Kanda, J., L. Kaynar, Y. Kanda, V. K. Prasad, S. H. Parikh, D. A. Rizzieri, G. D. Long, et al. “Use of Cyclosporine Is Associated with the Increase in Pre-Engraftment Syndrome After Myeloablative Dual Cord Blood Transplantation.” In Biology of Blood and Marrow Transplantation, 18:S332–S332. Elsevier BV, 2012. https://doi.org/10.1016/j.bbmt.2011.12.336.
       Full Text
    • Bacon, Wendi A., Gwynn D. Long, David A. Rizzieri, Mitchell E. Horwitz, John P. Chute, Keith M. Sullivan, Amanda Yopp, Angela Johns, Nelson J. Chao, and Cristina Gasparetto. “Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma.” In Blood, 118:1765–1765. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Beaven, Anne W., David A. Rizzieri, Zachary Powell, Zhiguo Li, Peggy Alton, Julie Warzecho, Louis F. Diehl, Joseph O. Moore, Carlos Manuel de Castro, and Jon P. Gockerman. “High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma.” In Blood, 118:1152–1152. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Cortes, Jorge E., Eric J. Feldman, Karen Yee, David A. Rizzieri, Anjali S. Advani, Anthony Charman, Martin J. Toal, and Hagop M. Kantarjian. “Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia.” In Blood, 118:348–348. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Cortes, Jorge E., Eric J. Feldman, Stuart L. Goldberg, David A. Rizzieri, Arthur C. Louie, and Jonathan E. Kolitz. “Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients.” In Blood, 118:1125–1125. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Cortes, Jorge E., Eric J. Feldman, Stuart L. Goldberg, David A. Rizzieri, Kim H. Paulsen, Arthur C. Louie, and Jonathan E. Kolitz. “CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report.” In Blood, 118:116–116. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Gasparetto, Cristina, Wendi A. Bacon, Phuong Doan, David A. Rizzieri, Mitchell E. Horwitz, John P. Chute, Keith M. Sullivan, et al. “High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation.” In Blood, 118:879–879. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Kanda, Junya, David A. Rizzieri, Gwynn D. Long, Cristina Gasparetto, John P. Chute, Keith M. Sullivan, Ashley Morris, et al. “The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation.” In Blood, 118:1736–1736. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Love, Cassandra L., Dereje Jima, Jenny Zhang, Vladimir Grubor, Rodney R. Miles, Cherie H. Dunphy, Kristy L. Richards, et al. “Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma.” In Blood, 118:199–200. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Morris, Tod A., David A. Rizzieri, Carlos M. de Castro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Joseph O. Moore, and Arati V. Rao. “Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia.” In Blood, 118:1532–33. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Rizzieri, David A., Norbert Vey, Richard F. Schlenk, Xavier Thomas, Francoise Huguet, Bjorn Gjertsen, Juergen Krauter, et al. “A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response.” In Blood, 118:666–67. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Kanda, J., M. E. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. P. Chute, A. Morris, T. Hennig, N. J. Chao, and D. A. Rizzieri. “Outcomes of a 1-Day Nonmyeloablative Preparative Regimen for Primary Graft Failure After Allogeneic Stem Cell Transplantation.” In Biology of Blood and Marrow Transplantation, 17:S308–S308. Elsevier BV, 2011. https://doi.org/10.1016/j.bbmt.2010.12.460.
       Full Text
    • Hutchinson, Charles Blake, Jennifer H. Crow, Huang Qin, Chuanyi M. Lu, Siby Sebastain, Catherine Rehder, Anand S. Lagoo, et al. “Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.” In Blood, 116:1423–24. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Jacobs, Cassandra L., Amee Patel, Dereje Jima, Qingquan Liu, Adrienne Greenough, Jenny Zhang, Cherie Dunphy, et al. “Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma.” In Blood, 116:351–52. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, Zhiguo Li, Nelson J. Chao, and David A. Rizzieri. “Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies..” In Blood, 116:1456–57. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Konopleva, Marina, Donna E. Hogge, David A. Rizzieri, Thomas P. Cirrito, Jen Sing Liu, Steven M. Kornblau, Margarite Grable, et al. “Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS.” In Blood, 116:1351–1351. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Lancet, Jeffrey E., B Douglas Smith, Robert Bradley, Rami S. Komrokji, Florentina Teofilovici, and David A. Rizzieri. “A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies.” In Blood, 116:1349–50. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Pettengell, Ruth, Pier Luigi Zinzani, Geetha Narayanan, Fernando Hurtado de Mendoza, Raghunadharao Digumarti, Henry Gomez, Bertrand Coiffier, et al. “Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.” In Blood, 116:1168–69. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Rizzieri, David A., Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, and Richard Larson. “Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002.” In Blood, 116:374–75. AMER SOC HEMATOLOGY, 2010.
       Link to Item
    • Doan, P. L., J. P. Chute, C. Gasparetto, M. Horwitz, D. Rizzieri, C. Smith, K. Sullivan, et al. “Long Term Survival Following High-dose Sequential Therapy with Autologous Hematopoietic Cell Rescue for Multiple Myeloma,” 16:S201–S201, 2010.
    • Coutre, Philipp D. le, Anna Turkina, Dong-Wook Kim, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, Zhixiang Shen, et al. “Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.” In Blood, 114:1272–73. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Coutre, Philipp D. le, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, Giuliana Alimena, Haifa Kathrin Al-Ali, Zhixiang Shen, et al. “Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study..” In Blood, 114:457–58. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Downie, Ben J., Harry P. Erba, Richard M. Stone, David A. Rizzieri, and James M. Foran. “Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy.” In Blood, 114:819–20. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Erba, Harry P., Margaret O’Donnell, Steven L. Allen, Maria R. Baer, Bayard L. Powell, Richard M. Stone, John M. Bennett, Ante S. Lundberg, Robert L. Capizzi, and David A. Rizzieri. “Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study..” In Blood, 114:433–34. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Jacobs, Cassandra L., Dereje D. Jima, Jenny Zhang, Cherie Dunphy, Kristy L. Richards, William W. L. Choi, Gopesh Srivastava, et al. “A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.” In Blood, 114:948–49. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Lanasa, Mark C., Patricia H. Davis, Michael Datto, Harry Cook, and David A. Rizzieri. “Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL..” In Blood, 114:1332–1332. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Lancet, Jeffrey E., Rami S. Komrokji, HuiYi Lin, Carlos M. de Castro, David A. Rizzieri, Magda Melchert, and Alan F. List. “Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission..” In Blood, 114:425–26. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Nicolini, Franck Emmanuel, Dong-Wook Kim, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, Zhixiang Shen, et al. “Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.” In Blood, 114:866–67. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • O’Brien, Susan, David A. Rizzieri, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, Mike Dennis, et al. “A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML..” In Blood, 114:431–431. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Pettengell, Ruth, Bertrand Coiffier, Geetha Narayanan, Fernando Hurtado de Mendoza, Raghunadharao Digumarti, Henry Gomez, Pier Luigi Zinzani, et al. “Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)..” In Blood, 114:669–669. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Powell, Bayard L., Hanna Jean Khoury, Jeffrey H. Lipton, David A. Rizzieri, Denise Williams, and A Robert Turner. “Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).” In Blood, 114:1277–1277. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Smith, Jason L., Amee Patel, Siyao Fan, Cassandra L. Jacobs, Katherine J. Walsh, Qingquan Liu, David A. Rizzieri, and Sandeep Dave. “Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway.” In Blood, 114:1436–37. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Tran, Trung N., G Thomas Ray, Patricia Saddier, Michael Trigg, Neil Hayes, Yan Li, David A. Rizzieri, et al. “Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm.” In Blood, 114:980–980. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Walsh, Katherine J., Siyao Fan, Amee Patel, Cassandra L. Jacobs, Jason L. Smith, Qingquan Liu, David A. Rizzieri, and Sandeep Dave. “PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-Dependent Proliferation..” In Blood, 114:676–676. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Giles, F. G., S. O’Brien, D. A. Rizzieri, N. Vey, U. Krug, M. Sekeres, T. F. Jacobsen, B. I. Nilsson, and K. Staudacher. “A phase II study with CP-4055 in patients with second salvage AML.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Rao, A. V., P. Valk, K. H. Metzeler, C. Acharya, D. A. Rizzieri, R. Delwel, S. H. Bohlander, C. Buske, A. Potti, and B. Lowenberg. “Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
       Link to Item
    • Chen, Dong-Feng, Vinod K. Prasad, Gloria Broadwater, Adella Clark, David A. Rizzieri, Nelson J. Chao, and Nancy L. Reinsmoen. “16-OR: Relevance of inhibitory and activating KIR and HLA ligand on outcomes in reduced intensity haploidentical peripheral blood stem cell transplants.” In Human Immunology, 69:S8–S8. Elsevier BV, 2008. https://doi.org/10.1016/j.humimm.2008.08.018.
       Full Text
    • Smith, G., D. A. Rizzieri, G. Alimena, H. -. K. Al-Ali, A. Zaritskey, Z. Shen, S. Jootar, Y. Hsu, M. L. Veronese, and F. E. Nicolini. “Expanding nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): updated safety analysis.” In British Journal of Haematology, 141:34–35. BLACKWELL PUBLISHING, 2008.
       Link to Item
    • Frankel, Arthur E., E. R. Smith, T. A. George, J. S. Liu, J. Lee, S. K. Park, David A. Rizzieri, and Donna E. Hogge. “Phase I study demonstrates activity and tolerability of diphtheria toxin interleukin-3 fusion protein in patients with AML and MDS.” In Blood, 110:273A-273A. AMER SOC HEMATOLOGY, 2007.
       Link to Item
    • Weinberg, J Brice, Alicia D. Volkheimer, Mirta Mihovilovic, Ning Jiang, Youwei Chen, Joseph O. Moore, Jon P. Gockerman, et al. “Apolipoprotein E (APOE) genotype as a determinant of survival in women with chronic lymphocytic leukemia.” In Blood, 110:906A-906A. AMER SOC HEMATOLOGY, 2007.
       Link to Item
    • Weinberg, J Brice, Ning Jiang, Alicia D. Volkheimer, Youwei Chen, Karen M. Bond, Joseph O. Moore, Jon P. Gockerman, et al. “Cytotoxicity of the type 4 phosphodiesterase inhibitor CD160130 for freshly isolated human CLL cells in vitro.” In Blood, 110:920A-921A. AMER SOC HEMATOLOGY, 2007.
       Link to Item
    • Adams, David J., Marit L. Sandvold, Fynn Myhren, Tove F. Jacobsen, and David A. Rizzieri. “Antiproliferative activity of ELACYT (TM) (CP-4055) in combination with cloretazine (VNP40101M), idarubicin or gemcitabine in HL-60 human myeloid leukemia cells..” In Blood, 108:563A-564A. AMER SOC HEMATOLOGY, 2006.
       Link to Item
    • Giles, Francis, Steven J. Freedman, Alan Xiao, Gautant Borthakur, Guillermo Garcia-Manero, William Wierda, Steven M. Kornblau, Susan O’Brien, Donald A. Bergstrom, and David A. Rizzieri. “MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL..” In Blood, 108:556A-557A. AMER SOC HEMATOLOGY, 2006.
       Link to Item
    • Giles, Francis, Steven J. Freedman, Alan Xiao, Gautant Borthakur, Guillermo Garcia-Manero, William Wierda, Steven M. Kornblau, Susan O’Brien, Donald A. Bergstrom, and David A. Rizzieri. “MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL..” In Blood, 108:556A-556A, 2006.
       Link to Item
    • Rizzieri, David A., William Tse, Khuda D. Khan, Anjali Advani, Jon Donze, Verena Karsten, Robert B. Geller, and Stanton L. Gerson. “A phase I study of cloretazine (R) and temozolomide in patients with hematologic malignancies..” In Blood, 108:557A-558A. AMER SOC HEMATOLOGY, 2006.
       Link to Item
    • Frankel, A. E., M. A. Weir, P. D. Hall, D. E. Hogge, and D. A. Rizzieri. “Diptheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML)..” In Journal of Clinical Oncology, 24:354S-354S, 2006.
       Link to Item
    • Prasad, V. K., D. -. F. Chen, N. L. Reinsmoen, G. Broadwater, N. J. Chao, and D. A. Rizzieri. “Impact of donor KIR genotype and recipient HLA ligand incompatibility on relapse related mortality and acute graft versus host disease in high-risk patients undergoing haploidentical non-myeloablative peripheral blood stem cell transplants: Differences between lymphoid and myeloid malignancies.” In Biology of Blood and Marrow Transplantation, 12:15–15. Elsevier BV, 2006. https://doi.org/10.1016/j.bbmt.2005.11.050.
       Full Text
    • Byrne, B. J., J. H. Antin, E. P. Alyea, N. J. Choa, and D. A. Rizzieri. “Efficacy of performing a second non-myeloablative allogenic stem cell transplant..” In Blood, 106:1020A-1020A, 2005.
       Link to Item
    • Gasparetto, C., G. P. Keogh, J. P. Gockerman, M. Horwitz, J. O. Moore, C. DeCastro, L. Diehl, P. Davis, N. Chao, and D. A. Rizzieri. “A prospective study of bortezomib in combination with melphalan and prednisone for patients with previously untreated multiple myeloma..” In Blood, 106:379B-379B. AMER SOC HEMATOLOGY, 2005.
       Link to Item
    • Misra, D., J. O. Moore, J. P. Gockerman, L. Diehl, C. de Castro, Y. P. Yang, C. Gasparetto, et al. “Phase I study of gemcitabine, fludarabine and mitoxantrone for relapsed or refractory leukemia..” In Blood, 106:235B-235B. AMER SOC HEMATOLOGY, 2005.
       Link to Item
    • Rizzieri, D. A., E. Feldman, J. O. Moore, G. J. Roboz, J. F. DiPersio, N. Gabrail, W. Stock, et al. “A phase 2 clinical trial of AP23573, an mTOR inhibitor, In patients with relapsed or refractory hematologic malignancies.” In Blood, 106:835A-836A. AMER SOC HEMATOLOGY, 2005.
       Link to Item
    • Rizzieri, D. A., L. P. Koh, G. D. Long, C. Gasparetto, J. Z. Gong, A. S. Lagoo, D. Niedzwiecki, et al. “Outcome and immune reconstitution following T cell depleted nonmyeloablative allogeneic transplantation using matched donors.” In Blood, 106:576A-576A. AMER SOC HEMATOLOGY, 2005.
       Link to Item
    • Rizzieri, D. A., L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, et al. “Partially HLA matched, non-myeloablative allogeneic transplantation.” In Blood, 106:812A-812A. AMER SOC HEMATOLOGY, 2005.
       Link to Item
    • Wanko, S. O., J. P. Gockerman, J. O. Moore, C. de Castro, L. Diehl, R. Pronitz, C. Gasparetto, et al. “Multimodal dose dense therapy for mantle cell lymphoma..” In Blood, 106:463B-463B. AMER SOC HEMATOLOGY, 2005.
       Link to Item
    • Chen, D. F., V. K. Prasad, G. Broadwater, D. A. Rizzieri, N. J. Chao, and N. L. Reinsmoen. “Impact of donor KIR genotype and recipient HLA ligand incompatibility on relapse-related mortality in high-risk patients undergoing haploidentical non-myeloablative peripheral blood stem cell transplants: Differences between lymphoid and myelloid malignanc.” In Tissue Antigens, 66:376–376. BLACKWELL PUBLISHING, 2005.
       Link to Item
    • Sebastian, S., C. W. Rehder, A. S. Lagoo, J. Z. Gong, P. J. Buckley, D. A. Rizzieri, and B. K. Goodman. “An unusual 4-way translocation resulting in a rare BCR-ABL fusion transcript (e13a3) and cytogenetic evolution in chronic myeloid leukemia (CML)..” In Journal of Molecular Diagnostics, 7:661–661. AMER SOC INVESTIGATIVE PATHOLOGY, INC, 2005.
       Link to Item
    • Grinblatt, D. L., J. Johnson, D. Niedzwicki, D. A. Rizzieri, N. Bartlett, and B. D. Cheson. “Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (Sll): CALGB study 50002.” In Blood, 104:897A-898A. AMER SOC HEMATOLOGY, 2004.
       Link to Item
    • Koh, L. P., J. P. Gockerman, J. O. Moore, C. DeCastro, G. D. Long, C. Gasparetto, D. Niedzwiecki, et al. “Dose dense, high intensity induction therapy followed by early high dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT) for mantle cell lymphoma (MCL)..” In Blood, 104:261A-261A. AMER SOC HEMATOLOGY, 2004.
       Link to Item
    • Misra, D., A. Frankel, P. Hall, T. F. Liu, J. Black, J. O. Moore, C. de Castro, et al. “The use of DT388-IL3 fusion protein in patients with refractory acute myeloid leukemia(AML).” In Blood, 104:212B-212B. AMER SOC HEMATOLOGY, 2004.
       Link to Item
    • Rao, A. V., D. A. Rizzieri, J. O. Moore, C. Decastro, A. P. Abernethy, M. Jordan, P. Davis, E. Edmonds, and J. P. Gockerman. “Dose dense, high intensity therapy in newly diagnosed elderly patients with acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg (TM)) and high dose cytarabine (HiDAC)..” In Blood, 104:212B-213B. AMER SOC HEMATOLOGY, 2004.
       Link to Item
    • Wanko, S. O., J. P. Gocherman, J. O. Moore, C. Decastro, R. Prosnitz, C. Gasparetto, J. Chute, et al. “Multimodal dose dense therapy for mantle cell lymphoma..” In Blood, 104:329A-330A. AMER SOC HEMATOLOGY, 2004.
       Link to Item
    • Gong, J. Z., D. Y. Trembath, B. K. Goodman, D. Quigley, S. Sebastian, D. A. Rizzieri, J. P. Gockerman, A. S. Lagoo, and P. J. Buckley. “Detection of genomic losses and gains in myelodysplastic syndrome and acute myeloid leukemia by array comparative genomic hybridization.” In Journal of Molecular Diagnostics, 6:420–420. AMER SOC INVESTIGATIVE PATHOLOGY, INC, 2004.
       Link to Item
    • Akabani, G., D. A. Rizzieri, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, et al. “Phase I trial study of [131]I-labeled chimeric 81C6 mAb for the treatment of patients with non-Hodgkin's lymphoma.” In European Journal of Nuclear Medicine and Molecular Imaging, 31:S222–S222. SPRINGER, 2004.
       Link to Item
    • Castro, C. M. de, H. Uronis, J. O. Moore, J. P. Gockerman, D. A. Rizzieri, and N. J. Chao. “Successful treatment of pure red cell aplasia (PRCA) with alemtuzumab (CAMPATH-1H)..” In Blood, 102:19B-19B. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Gasparetto, C., N. J. Chao, M. E. Horwitz, J. O. Moore, C. DeCastro, J. Gockerman, K. Sullivan, et al. “Pharmacokinetics of subcutaneous alemtuzumab in a patient with myeloma..” In Blood, 102:385B-385B. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Goggins, T. F., D. A. Rizzieri, R. Prosnitz, C. Gasparetto, G. Long, M. E. Horwitz, K. Sullivan, et al. “One day preparative regimen for allogeneic non-myeloablative stem cell transplantation (NMSCT) using 3-5/6 HLA matched related donors..” In Blood, 102:476B-477B. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Rizzieri, D. A., G. Akabani, M. Zalutsky, R. E. Coleman, B. Toaso, E. Anderson, A. Lagoo, et al. “Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma..” In Blood, 102:635A-636A. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Rizzieri, D. A., G. J. Sand, D. McGaughey, J. Moore, C. DeCastro, N. Chao, J. Vredenburgh, et al. “Low-dose weekly paclitaxel for relapsed or refractory aggressive non-Hodgkins lymphoma..” In Blood, 102:641A-641A. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Rizzieri, D. A., L. P. Koh, G. D. Long, A. S. Lagoo, C. Gasparatto, J. J. Vredenburgh, P. J. Buckley, et al. “Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings..” In Blood, 102:238A-239A. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Rizzieri, D. A., L. P. Koh, G. D. Long, C. Gasparetto, J. J. Vredenburgh, P. J. Buckley, G. Gong, et al. “Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells..” In Blood, 102:482A-482A. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Sand, G. J., J. O. Moore, C. DeCastro, J. P. Gockerman, B. Peterson, P. J. Buckley, B. Toaso, D. Adams, and D. A. Rizzieri. “Phase one evaluation of gemcitabine, fludarabine, and mitoxantrone for relapsed or refractory leukemia..” In Blood, 102:250B-250B. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Talbot, J. T., V. K. Ibom, R. Barrier, D. Niedzwieki, C. M. Castro, J. O. Moore, P. J. Buckley, et al. “Dose-intense cyclophosphamide and etoposide for patients with refractory or high risk non-Hogdkin's lymphoma..” In Blood, 102:287B-287B. AMER SOC HEMATOLOGY, 2003.
       Link to Item
    • Snyder, M. J., T. T. Stenzel, A. S. Lagoo, D. A. Rizzieri, N. Chao, P. J. Buckley, and J. Z. Gong. “Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation.” In Laboratory Investigation, 83:253A-253A. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Snyder, M. J., T. T. Stenzel, A. S. Lagoo, D. A. Rizzieri, N. Chao, P. J. Buckley, and J. Z. Gong. “Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation.” In Modern Pathology, 16:253A-253A. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Foran, J., M. Wetzler, H. M. Karitarjian, S. Faderl, N. Abramson, D. A. Rizzieri, A. Craig, J. Weiss, and D. Douer. “A phase II, open-label study of CLOPAREX(TM) in adult patients with refractory or relapsed acute myelogenous leukemia.” In Blood, 100:271B-271B, 2002.
       Link to Item
    • Gandy, K. L., N. J. Chao, G. D. Long, V. Sartain, H. F. Seigler, and D. A. Rizzieri. “Donor-specific tolerance after hematopoietic reconstitution with Campath-1H treated mobilized peripheral blood cells in a sublethal preconditioning regimen..” In Blood, 100:410A-410A. AMER SOC HEMATOLOGY, 2002.
       Link to Item
    • Isola, L. M., J. N. Chao, S. Weinberg, S. M. Fruchtman, G. Atweh, S. McCune, M. J. Telen, et al. “Donor chimerism after T-Cell depleted (TCD)-Non-Myeloablative allogeneic SCT (NST) in hemoglobinopathies..” In Blood, 100:401B-402B. AMER SOC HEMATOLOGY, 2002.
       Link to Item
    • Johnston, L. J., J. S. Shizuru, K. E. Stockerl-Goldstein, M. J. Stuart, C. Gasparetto, G. D. Long, D. A. Rizzieri, et al. “GLAT (Copaxone) for treatment of steroid-refractory acute graft versus host disease..” In Blood, 100:421A-421A, 2002.
       Link to Item
    • Koh, L. P., D. A. Rizzieri, G. D. Long, J. J. Vredenburgh, C. Gaparetto, A. Morris, B. Water-Picks, et al. “Campath-1H, T cell depleted nonmyeloablative peripheral blood stem cell transplantation from 3-6/6 HLA matched family members..” In Blood, 100:638A-638A. AMER SOC HEMATOLOGY, 2002.
       Link to Item
    • Lonial, S., D. A. Rizzieri, L. P. Koh, M. Jones, A. A. Langston, I. Redei, G. D. Long, et al. “Three methods of T-cell depletion of HPCT products: Analysis of CD34+ cell and lymphocyte purity and recovery..” In Blood, 100:835A-836A. AMER SOC HEMATOLOGY, 2002.
       Link to Item
    • Rai, K. R., M. J. Keating, S. Coutre, D. A. Rizzieri, and Campath Study Grp. “Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath (R)) on a compassionate basis. A report on efficacy and safety of CAM 511 trial..” In Blood, 100:802A-802A, 2002.
       Link to Item
    • Morse, M. A., D. Rizzieri, A. C. Hobeika, N. Chao, and H. Kirn Lyerly. “Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants.” In Blood, Vol. 96, 2000.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.